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INHIBITION	  OF	  A	  TRUNCATED	  FORM	  OF	  HUMAN	  MITOCHONDRIAL	  KIDNEY-­‐TYPE	  
GLUTAMINASE	  (hKGA124-­‐551)	  BY	  BIS-­‐2-­‐(5-­‐PHENYLACTAMIDO-­‐1,2,4-­‐THIALDIAZOL-­‐
2-­‐YL)ETHYL	  SULFIDE	  (BPTES)	  
	  
Mitochondrial	  glutaminase	  (GA)	  catalyzes	  the	  hydrolysis	  of	  glutamine	  producing	  
glutamate	  and	  an	  ammonium	  ion.	  There	  are	  three	  isoforms	  of	  mammalian	  GA	  that	  
are	  essential	  to	  hepatic	  ureagenesis,	  renal	  ammoniagenesis,	  synthesis	  of	  the	  
neurotransmitter	  glutamate,	  and	  the	  catabolism	  of	  glutamine.	  	  Here	  we	  focus	  on	  the	  
human	  KGA	  isoform	  that	  is	  predominantly	  expressed	  in	  kidney,	  brain,	  intestine,	  and	  
tissues	  of	  the	  immune	  system.	  	  Recent	  publications	  suggest	  that	  GA	  is	  a	  novel	  target	  
for	  developing	  new	  cancer	  therapeutics.	  	  These	  studies	  have	  indicated	  that	  
inhibition	  of	  GA	  by	  small	  molecule	  inhibitors	  significantly	  reduces	  the	  size	  of	  tumors	  
in	  rats	  and	  inhibits	  growth	  of	  transformed	  cells	  in	  culture.	  	  A	  truncated	  form	  of	  
human	  KGA	  (hKGA124-­‐551)	  that	  contains	  amino	  acids	  124-­‐551,	  was	  produced	  to	  
delete	  the	  C-­‐terminal	  sequences	  that	  are	  unique	  to	  the	  KGA	  and	  GAC	  isoforms.	  	  This	  
construct	  was	  assayed	  in	  the	  presence	  of	  (bis-­‐2-­‐(5-­‐phenylactamido-­‐1,2,4-­‐thiadiazol-­‐
2-­‐yl)ethyl	  sulfide	  (BPTES).	  	  BPTES	  is	  a	  potent	  small	  molecule	  inhibitor	  of	  
mammalian	  GA	  that	  was	  previously	  shown	  to	  inhibit	  rat	  KGA	  in	  µM	  concentrations.	  	  
In	  the	  current	  study,	  we	  adapted	  the	  standard	  GA	  assay	  to	  a	  microtiter	  plate	  format	  
and	  used	  it	  to	  characterize	  the	  inhibition	  of	  hKGA124-­‐551	  using	  µM	  amounts	  of	  BPTES.	  
	  
iii	  
Our	  data	  indicate	  that	  BPTES	  is	  a	  mixed	  non-­‐competitive	  inhibitor	  at	  low	  
concentrations	  of	  phosphate,	  but	  at	  higher	  phosphate	  concentrations	  the	  inhibition	  
is	  predominantly	  uncompetitive.	  	  Lastly,	  gel	  filtration	  and	  dynamic	  light	  scattering	  
experiments	  were	  performed	  to	  determine	  if	  hKGA124-­‐551	  oligomers	  are	  formed	  in	  
the	  presence	  of	  BPTES	  and	  to	  characterize	  the	  effect	  of	  increasing	  concentrations	  of	  
phosphate.	  	  The	  data	  suggest	  that	  in	  the	  absence	  or	  presence	  of	  phosphate	  and	  in	  
the	  absence	  of	  BPTES,	  the	  hKGA124-­‐551	  exists	  as	  a	  dimer,	  but	  in	  the	  presence	  of	  
BPTES	  the	  molecular	  weight	  shifts	  to	  a	  tetramer	  or	  higher	  oligomer.	  	  The	  combined	  
data	  indicate	  that	  BPTES	  is	  a	  potent	  lead	  compound	  for	  the	  development	  of	  a	  
therapeutic	  inhibitor	  of	  human	  GA	  that	  may	  be	  a	  potential	  cancer	  therapeutic.	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Mitochondrial	  glutaminase	  (GA)	  catalyzes	  the	  hydrolysis	  of	  glutamine	  producing	  
glutamate	  and	  ammonium	  ion	  (1).	  	  GA	  is	  localized	  to	  the	  mitochondrial	  matrix.	  	  It	  
contains	  an	  amphipathic	  α-­‐helix	  encoded	  within	  exon	  1	  that	  is	  required	  to	  target	  GA	  
to	  the	  mitochondrion	  (2).	  	  GA	  is	  essential	  to	  hepatic	  ureageneisis	  (1),	  renal	  
ammoniagenisis	  (3,	  4),	  synthesis	  of	  the	  neurotransmitter	  glutamate	  (5-­7),	  and	  the	  
catabolism	  of	  glutamine	  as	  an	  energy	  source	  (1,	  8-­10).	  
There	  are	  three	  isoforms	  of	  mammalian	  GA	  encoded	  by	  two	  separate	  genes	  (11,	  
12).	  The	  liver	  type	  glutaminase	  (LGA)	  is	  encoded	  by	  18	  exons	  on	  chromosome	  12.	  	  
The	  kidney	  type	  glutaminase	  (KGA)	  gene	  spans	  82	  kb	  on	  chromosome	  2	  and	  
encodes	  19	  exons.	  	  KGA	  lacks	  sequence	  encoded	  by	  exon	  15,	  but	  does	  include	  
sequence	  from	  exons	  1-­‐14	  and	  16-­‐19.	  	  The	  glutaminase	  variant	  (GAC)	  is	  an	  
alternatively	  spliced	  isoform	  of	  the	  kidney	  type	  glutaminase.	  	  GAC	  contains	  
sequence	  encoded	  by	  exons	  1-­‐15	  and	  is	  predominantly	  expressed	  the	  heart,	  
pancreas,	  placenta,	  and	  lungs.	  	  The	  KGA	  isoform	  is	  predominantly	  expressed	  in	  
kidney,	  brain,	  intestine,	  and	  tissues	  of	  the	  immune	  system	  (11).	  Comparison	  of	  three	  
GA	  isoforms	  shows	  that	  human	  hLGA	  and	  hKGA	  have	  distinct	  N	  terminal	  sequences	  
(Figure	  1).	  	  All	  three	  isoforms	  have	  different	  C-­‐termini;	  however,	  all	  isoforms	  share	  
a	  common	  highly	  conserved	  core	  sequence	  (13).	  	  This	  core	  sequence	  is	  also	  similar	  
to	  the	  bacterial	  glutaminase	  suggesting	  that	  the	  core	  sequence,	  located	  in	  the	  middle,	  


























	  	  	   	  
	  
Figure	  1	  Comparison	  of	  human	  glutaminase	  isoforms	  and	  bacterial	  
glutaminase	  
The	  three	  human	  glutaminase	  isoforms,	  kidney	  type	  glutaminase	  (hKGA),	  
the	  kidney	  type	  glutaminase	  variant	  (hGAC),	  and	  the	  liver	  type	  
glutaminase	  (hLGA),	  are	  compared	  to	  the	  bacterial	  glutaminase.	  	  There	  is	  a	  
common	  core	  in	  the	  middle	  of	  the	  enzyme	  that	  is	  highly	  conserved	  in	  each	  
glutaminase	  isoform	  that	  is	  represented	  by	  the	  black	  bar.	  	  hKGA	  and	  hGAC	  
isoforms	  share	  an	  identical	  N-­‐terminus,	  which	  differs	  from	  the	  hLGA	  





The	  catabolism	  of	  glutamine	  plays	  a	  central	  role	  in	  cellular	  metabolism.	  	  
Glutamine	  catabolism	  is	  involved	  in	  ureagenisis	  in	  hepatic	  tissue	  and	  is	  strongly	  
activated	  in	  renal	  tissue	  during	  onset	  of	  metabolic	  acidosis	  (1,	  3,	  4).	  	  The	  conversion	  
of	  glutamine	  to	  glutamate	  by	  GA	  followed	  by	  subsequent	  deamination	  by	  glutamate	  
dehydrogenase	  leads	  to	  the	  formation	  of	  α-­‐ketoglutarate	  (1).	  	  The	  further	  
catabolism	  of	  α-­‐ketoglutarate	  in	  the	  TCA	  cycle	  produces	  the	  high-­‐energy	  electron	  
carrier	  molecules,	  reduced	  nicotinamide	  adenine	  dinucleotide (NADH)	  and	  flavin	  
adenine	  dinucleotide	  (FADH),	  for	  oxidative	  phosphorlyation	  and	  can	  lead	  to	  the	  
production	  of	  glucose	  through	  gluconeogenisis	  (1).	  α-­‐Ketoglutarate	  can	  also	  be	  used	  
to	  produce	  the	  amino	  acids	  aspartic	  acid	  and	  asparagine	  by	  transamination	  of	  
oxaloacetate	  and	  a	  subsequent	  amidotransferase	  reaction,	  respectively.	  	  The	  
formation	  of	  glutamate	  by	  either	  a	  transamination	  reaction	  or	  the	  glutaminase	  
reaction	  can	  lead	  to	  the	  production	  of	  the	  amino	  acids	  proline	  and	  arginine	  as	  well	  
as	  other	  metabolites	  central	  to	  the	  formation	  of	  urea	  such	  as	  ornithine	  and	  citralline.	  	  	  
Since	  glutamine	  plays	  such	  a	  vast	  role	  in	  cellular	  metabolism	  and	  the	  production	  
of	  high-­‐energy	  molecules	  it	  has	  been	  suggested	  that	  glutamine	  is	  an	  essential	  fuel	  for	  
rapidly	  dividing	  tissues	  and	  cancer	  cells	  (8,	  14,	  15).	  	  Recent	  studies	  have	  indicated	  
that	  the	  metabolism	  of	  glutamine	  is	  just	  as	  important	  as	  the	  metabolism	  of	  glucose	  
in	  cancer	  cells	  and	  transformed	  cell	  cultures	  (8,	  15).	  	  It	  has	  been	  long	  established	  
that	  the	  transport	  and	  metabolism	  of	  glucose	  leading	  to	  the	  formation	  of	  lactic	  acid	  
is	  significantly	  increased	  in	  cancer	  cells,	  as	  explained	  by	  the	  Warburg	  effect	  (9,	  16,	  
17).	  	  The	  Warburg	  effect	  suggests	  that	  the	  catabolism	  of	  glucose	  is	  increased	  
significantly,	  but	  is	  largely	  utilized	  for	  the	  production	  of	  lactic	  acid	  even	  under	  
	  
4	  
aerobic	  conditions	  (9)	  (Figure	  2).	  	  The	  increased	  production	  of	  lactic	  acid	  is	  
inefficient	  when	  compared	  to	  the	  ATP	  production	  through	  oxidative	  
phosphorylation.	  	  	  However,	  recent	  publications	  suggest	  that	  the	  uptake	  of	  
glutamine	  is	  also	  significantly	  increased,	  indicating	  that	  glucose	  catabolism	  is	  not	  
the	  only,	  or	  even	  the	  main	  source	  of	  energy	  for	  cancer	  cells	  and	  transformed	  cells	  (8,	  
16,	  18)	  (Figure	  3).	  	  New	  studies	  indicate	  that	  inhibition	  of	  mitochondrial	  kidney-­‐type	  
glutaminase	  by	  siRNA	  knock-­‐down	  and	  small	  molecule	  inhibitors	  can	  reduce	  the	  
growth	  and	  size	  of	  tumors	  in	  rats	  and	  transformed	  cell	  culture	  (15,	  19).	  	  This	  recent	  
data	  suggests	  that	  GA	  is	  a	  target	  for	  developing	  novel	  cancer	  therapeutics.	  
Furthermore,	  current	  studies	  suggest	  Rho	  family	  GTPases	  and	  the	  Dbl	  protein	  
family	  are	  involved	  not	  only	  in	  transformation	  of	  cells,	  but	  are	  also	  responsible	  for	  
the	  increased	  glutamine	  catabolism	  by	  activating	  GA	  (8).	  	  Rho	  family	  GTPases	  act	  as	  
a	  super	  regulator,	  or	  switch,	  that	  mediates	  signal	  transduction	  from	  the	  plasma	  
membrane	  to	  alter	  cell	  polarity,	  gene	  transcription,	  cell	  cycle	  progression	  and	  
regulation,	  microtubule	  dynamics,	  vesicle	  transport,	  and	  enzymatic	  activities	  (20).	  	  
Small	  GTPases	  are	  regulated	  in	  part	  by	  the	  binding	  and	  hydrolysis	  of	  GTP.	  	  Guanine	  
nucleotide	  exchange	  factors	  (GEFs)	  aid	  in	  the	  binding	  of	  GTP	  activating	  small	  
GTPases	  like	  the	  Rho	  family.	  	  GTPase	  activating	  proteins	  (GAPs)	  aid	  in	  the	  hydrolysis	  
of	  GTP	  resulting	  in	  inorganic	  phosphate	  and	  GDP	  bound,	  inactive	  GTPase.	  	  GTPases	  
can	  also	  be	  regulated	  by	  guanine	  nucleotide	  exchange	  factor	  inhibitors	  (GDIs),	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Figure	  2.	  The	  Warburg	  Effect	  
The	  metabolic	  flux	  between	  a	  quiescent	  cell	  (left	  panel)	  and	  a	  proliferating	  cell	  (right	  
panel)	  as	  described	  by	  the	  Warburg	  effect.	  	  During	  a	  quiescent	  cell	  state	  glucose	  is	  
catabolized	  through	  the	  glycolytic	  pathway	  and	  fully	  oxidized	  in	  the	  TCA	  cycle.	  	  This	  
produces	  the	  needed	  electron	  carriers	  for	  oxidative	  phosphorylation	  producing	  large	  
quantities	  of	  ATP	  (stars).	  	  During	  a	  proliferating	  cellular	  state	  the	  metabolic	  flux	  
changes	  significantly	  under	  aerobic	  conditions.	  	  Larger	  quantities	  of	  glucose	  are	  
consumed;	  however,	  glucose	  is	  not	  fully	  oxidized	  through	  the	  TCA	  cycle	  generating	  
the	  needed	  ATP.	  	  Majority	  of	  the	  glucose	  is	  catabolized	  leading	  to	  the	  formation	  of	  
lactic	  acid.	  	  As	  indicated	  by	  the	  diagram,	  most	  of	  the	  ATP	  generated	  is	  through	  the	  
glycolytic	  pathway	  only	  forming	  small	  quantities	  of	  pyruvate	  for	  citrate	  synthesis.	  	  
This	  leads	  to	  current	  debate	  of	  how	  cells	  can	  maintain	  the	  needed	  energy	  
requirement	  for	  cellular	  growth	  and	  division	  while	  producing	  high-­‐energy	  molecules	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Figure	  3.	  The	  Addition	  to	  the	  Warburg	  Effect	  
During	  a	  cellular	  proliferative	  state	  there	  needed	  to	  exist	  an	  alternative	  energy	  source	  to	  
fill	  the	  energy	  void.	  	  As	  discussed	  previously	  proliferating	  cells	  in	  the	  presence	  of	  oxygen	  
significantly	  increase	  their	  glucose	  consumption	  increasing	  the	  metabolic	  flux	  through	  
the	  glycolytic	  pathway.	  	  The	  increased	  glycolytic	  flux	  predominantly	  leads	  to	  the	  
formation	  of	  lactic	  acid	  generating	  small	  amounts	  of	  pyruvate.	  	  The	  generated	  pyruvate	  
can	  then	  enter	  the	  TCA	  cycle	  forming	  citrate	  for	  fatty	  acid	  synthesis.	  	  The	  alternative	  
energy	  source	  for	  proliferating	  cells	  is	  the	  catabolism	  of	  the	  amino	  acid	  glutamine.	  	  
Glutamine	  consumption	  is	  increased	  during	  cellular	  proliferation.	  	  Glutamine	  is	  
converted	  to	  glutamate	  in	  the	  glutaminase	  (GLS)	  reaction	  producing	  a	  free	  ammonium	  
ion	  forming	  glutamate.	  	  Glutamate	  is	  subsequently	  reacted	  forming	  α-­‐ketoglutarate.	  α-­‐
ketoglutarate	  is	  primary	  component	  for	  the	  TCA	  cycle	  which	  is	  able	  to	  produce	  the	  
needed	  high-­‐energy	  electron	  carriers	  for	  oxidative	  phosphorlylation.	  It	  is	  important	  to	  
note	  that	  this	  review	  studied	  cellular	  proliferation	  under	  c-­myc	  induction	  and	  found	  that	  
not	  only	  are	  glucose	  and	  glutamine’s	  uptake	  increased,	  but	  the	  micro-­‐RNA’s	  miR23a	  and	  
miR23b	  regulate	  glutaminase	  activity.	  	  Upon	  c-­‐myc	  induction	  miR23a/b	  are	  repressed	  




GTPases	  sequestering	  them	  from	  the	  plasma	  membrane	  (20,	  21).	  Dbl	  family	  proteins	  
are	  oncogene	  products	  which	  share	  Dbl	  homology	  (DH)	  and	  pleckstrin	  homology	  
(PH)	  domains	  and	  act	  as	  GEFs	  of	  the	  Ras	  and	  Rho	  family	  GTPases	  (22,	  23).	  	  The	  
increased	  activity	  of	  Dbl	  proteins	  enhances	  the	  activation	  of	  Rho-­‐like	  small	  GTPases	  
and	  influences	  cellular	  transformation	  (22).	  	  A	  recent	  publication	  by	  Erikson	  and	  
Cerione	  linked	  GA	  to	  constitutively	  active	  Rho	  GTPases	  and	  oncogenic	  Dbl	  induced	  
cellular	  transformation	  (8).	  	  They	  screened	  for	  potential	  drugs	  that	  attenuated	  the	  
transformed	  phenotype	  produced	  by	  the	  over-­‐expression	  of	  Dbl.	  	  The	  identified	  
inhibitor	  of	  transformation	  (molecule	  968)	  was	  shown	  to	  bind	  to	  and	  inhibit	  the	  
glutaminase	  variant	  (GAC)	  isoform	  (8).	  	  Recent	  studies	  also	  suggest	  that	  over	  
expression	  of	  the	  oncogene	  myc	  not	  only	  caused	  cellular	  transformation	  and	  
increased	  anaerobic	  glycolysis,	  but	  also	  activated	  glutamine	  metabolism	  (10,	  18).	  	  
Upon	  myc	  induction,	  the	  micro-­‐RNAs	  miR23a	  and	  miR23b	  are	  suppressed,	  resulting	  
in	  increased	  GA	  expression	  and	  activity	  (24).	  	  	  	  
Previous	  studies	  have	  indicated	  that	  the	  N-­‐terminal	  72	  amino	  acid	  sequence	  is	  
removed	  following	  translocation	  of	  GA	  into	  the	  mitochondrion	  (2).	  	  hKGA128-­‐669,	  a	  
construct	  that	  contains	  amino	  acids	  128-­‐669,	  was	  previously	  expressed	  to	  mimic	  the	  
mature	  KGA	  isoform.	  	  A	  second	  construct,	  hKGA124-­‐551,	  that	  contains	  amino	  acids	  
124-­‐551	  was	  produced	  to	  delete	  the	  C-­‐terminal	  sequences	  that	  are	  unique	  to	  the	  
KGA	  and	  GAC	  isoforms.	  	  A	  third	  construct	  hKGA221-­‐532	  was	  cloned	  to	  express	  an	  N-­‐
terminal	  and	  C-­‐terminal	  truncation.	  	  hKGA221-­‐532	  was	  recently	  crystallized	  in	  the	  
presence	  of	  glutamate	  by	  the	  Structural	  Genomics	  Consortium	  (SGC)(PDB	  ID	  3CZD).	  	  
However,	  our	  construct	  differs	  from	  the	  SGC	  construct	  because	  it	  lacks	  a	  tobacco	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etch	  virus	  (TEV)	  proteolytic	  cleavage	  tag	  which	  removes	  the	  N-­‐terminal	  his6-­‐tag.	  	  
Figure	  4	  shows	  each	  of	  the	  constructs	  considered	  for	  kinetic	  study.	  	  
The	  hKGA	  truncated	  constructs	  where	  assayed	  in	  the	  presence	  of	  bis-­‐2-­‐(5-­‐
phenylactamido-­‐1,2,4-­‐thiadiazol-­‐2-­‐yl)ethyl	  sulfide	  (BPTES).	  	  BPTES	  is	  a	  potent	  
inhibitor	  of	  mammalian	  GA	  that	  inhibits	  rat	  KGA	  deletion	  constructs	  in	  µM	  
concentrations	  (7).	  	  BPTES	  inhibits	  rKGA∆1	  as	  a	  mixed	  non-­‐competitive	  inhibitor.	  	  
Past	  inhibition	  studies	  have	  shown	  that	  BPTES	  does	  not	  bind	  to	  active	  site	  of	  
mammalian	  KGA.	  Mammalian	  KGA	  exists	  as	  an	  inactive	  dimer	  in	  the	  absence	  of	  
phosphate,	  but	  forms	  an	  active	  tetramer	  in	  the	  presence	  of	  phosphate(7,	  25-­27).	  	  
Analytical	  ultra-­‐centrifugation	  studies	  indicate	  that	  when	  BPTES	  binds,	  rat	  KGA∆1	  
forms	  stable,	  but	  inactive	  tetramers	  (7).	  	  Inhibition	  studies	  suggest	  that	  BPTES	  binds	  
allosterically	  to	  tetramers,	  thereby	  altering	  the	  conformation	  of	  the	  active	  complex.	  	  
BPTES	  ability	  to	  inhibit	  KGA	  at	  low	  concentrations	  and	  with	  high	  specificity	  makes	  it	  
a	  potential	  lead	  compound	  for	  drug	  studies.	  	  Other	  inhibitors	  such	  as	  6-­‐diazo-­‐5-­‐oxo-­‐
L-­‐norleucine	  (DON),	  a	  glutamine	  analogue,	  inhibit	  mammalian	  GA	  in	  a	  competitive	  
manner	  with	  less	  specificity.	  	  It	  has	  been	  suggested	  that	  DON	  preferentially	  interacts	  
with	  active	  KGA;	  conversely,	  the	  inhibitor	  L-­‐2-­‐amino-­‐4-­‐oxo-­‐5-­‐chloropentanoic	  acid	  
(CK)	  interacts	  with	  dimeric	  KGA.	  	  DON,	  but	  not	  CK,	  requires	  phosphate	  to	  inactivate	  
mammalian	  GA.	  	  DON	  inhibition	  is	  enhanced	  in	  the	  presence	  of	  phosphate	  and	  
inhibition	  by	  CK	  is	  decreased	  in	  the	  presence	  of	  phosphate	  (28,	  29).	  Inhibitors	  like	  








Figure	  4.	  hKGA	  Constructs	  for	  Kinetic	  Analysis	  
The	  KGA	  constructs	  considered	  for	  kinetic	  study	  all	  include	  N-­‐terminal	  His6-­‐tags.	  	  
The	  hKGA128-­‐669	  construct	  contains	  amino	  acids	  128-­‐669.	  	  This	  construct	  was	  
produced	  to	  mimic	  a	  full	  length	  wild-­‐type	  KGA	  because	  the	  first	  100	  amino	  acids	  
are	  required	  to	  target	  KGA	  to	  the	  mitochondrion	  and	  is	  not	  retained	  in	  the	  
mature	  protein.	  	  This	  construct	  contains	  the	  C-­‐terminal	  sequence	  specific	  to	  the	  
KGA	  isoform.	  	  The	  hKGA221-­‐532	  is	  a	  N-­‐terminal	  and	  C-­‐terminal	  deletion	  construct,	  
which	  was	  recently	  crystallized	  by	  the	  SGC.	  	  The	  hKGA124-­‐551	  construct	  contains	  
the	  N-­‐terminal	  sequence	  of	  the	  mature	  KGA	  isoform	  but	  lacks	  the	  C-­‐terminal	  
sequence	  specific	  to	  the	  KGA	  enzyme.	  	  The	  last	  construct,	  hKGA221-­‐669,	  contains	  




LGA	  activity	  and	  are	  not	  ideal	  lead	  compounds	  for	  drug	  targeting	  because	  they	  lack	  
specificity	  and	  sufficient	  affinity	  for	  the	  mammalian	  KGA.	  	  Figure	  5	  contains	  the	  
structures	  of	  the	  substrate	  and	  product	  of	  the	  glutaminase	  reaction	  along	  with	  the	  
four	  inhibitors	  described	  above	  DON,	  CK,	  BPTES,	  and	  molecule	  968.	  
Our	  approach	  is	  to	  study	  the	  hKGA124-­‐551	  construct	  to	  determine	  if	  it	  retains	  
properties	  characteristic	  of	  the	  mammalian	  GA.	  	  Basic	  activity	  will	  be	  established,	  as	  
well	  as	  kinetic	  profiles	  for	  this	  construct,	  including	  the	  kinetic	  constants	  Km,	  Vmax,	  
and	  Ki.	  	  Lastly,	  phosphate	  activation	  profiles	  will	  be	  compiled	  to	  determine	  if	  this	  
deletion	  construct	  exhibits	  the	  phosphate-­‐dependent	  activation	  and	  









Figure	  5.	  Structural	  Players	  
At	  the	  top	  are	  the	  structural	  representations	  of	  the	  substrate,	  glutamine,	  and	  the	  
product,	  glutamate,	  of	  the	  glutaminase	  reaction.	  	  The	  inhibitors	  DON	  and	  CK	  are	  
in	  the	  middle	  and	  share	  great	  structural	  homology	  to	  the	  glutaminase	  product	  
and	  substrate.	  	  The	  last	  two	  inhibitors	  are	  BTPES	  and	  molecule	  968	  which	  are	  






Cloning	  of	  hKGA124-­551	  
hKGA124-­‐551	  was	  cloned	  using	  hKGA	  4	  as	  the	  parent	  plasmid	  (30)	  which	  contains	  
the	  complete	  hKGA	  coding	  region.	  	  Forward	  and	  reverse	  primers	  where	  used	  to	  
amplify	  the	  desired	  segment.	  The	  sequence	  incorporated	  NdeI	  and	  BamHI	  
restriction	  sites	  at	  the	  5’	  and	  3’	  ends,	  respectively.	  	  The	  insert	  was	  shuttled	  through	  
the	  pGEM-­‐T	  easy	  vector	  and	  then	  ligated	  into	  the	  pET-­‐15b	  expression	  vector.	  	  The	  
plasmid,	  pET-­‐15b	  rKGAΔ1,	  was	  cut	  with	  NdeI	  and	  BamHI	  restriction	  enzymes	  to	  
remove	  the	  rKGAΔ1	  insert.	  pET-­‐15b	  rKGAΔ1	  	  is	  an	  expression	  plasmid	  containing	  the	  
rat	  isoform	  of	  KGA	  lacking	  the	  sequence	  encoded	  by	  exon	  1.	  	  The	  insert	  (1295	  bp)	  
containing	  hKGA124-­‐551	  sequence	  was	  cut	  out	  of	  the	  pGEM-­‐T	  easy	  plasmid	  and	  ligated	  
into	  the	  pET-­‐15b	  vector	  fragment	  (5700	  bp)	  using	  Quick	  Stick	  Ligation	  kit	  resulting	  
in	  a	  pET-­‐15b	  hKGA124-­‐551	  plasmid.	  DNA	  sequencing	  across	  the	  entire	  insert	  
confirmed	  the	  plasmid	  identity.	  	  	  
	  
Protein	  expression	  and	  purification	  
Recombinant	  protein	  expression	  of	  pET-­‐15b	  hKGA124-­‐551,	  an	  N-­‐	  and	  C-­‐terminal	  
truncation	  of	  human	  glutaminase,	  was	  performed	  using	  Escherichia	  coli	  strain	  BL-­‐21	  
(DE3)	  that	  contained	  the	  Rosetta	  pRARE	  plasmid.	  	  The	  E.	  coli	  strain	  was	  obtained	  
from	  the	  Structural	  Genomics	  Consortium	  (SGC)	  at	  the	  Karolinska	  Institutet.	  	  Cell	  
cultures	  were	  grown	  in	  6	  L	  of	  medium	  at	  37°C	  to	  an	  O.D.600	  of	  1.0-­‐1.5	  and	  then	  
cooled	  to	  18°C	  before	  being	  induced	  with	  0.5	  mM	  IPTG.	  	  Cultures	  were	  harvested	  the	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following	  morning	  by	  centrifugation	  at	  4000	  rpm	  at	  4°C	  for	  30	  minutes.	  Harvested	  
cell	  pellets	  were	  resuspended	  in	  50	  mL	  of	  lysis	  buffer	  containing	  300	  mM	  KCl,	  10%	  
glycerol	  (v/v),	  10	  mM	  Tris-­‐Cl,	  pH	  8.0,	  10	  mM	  potassium	  phosphate,	  10	  mM	  
imidazole,	  0.5	  mM	  Tris(2-­‐carboxyethyl)phosphine	  hydrocloride	  (TCEP),	  a	  potent	  
and	  stable	  reducing	  agent,	  and	  one	  tablet	  of	  Complete	  Protease	  Inhibitor	  Cocktail	  
(Roche).	  	  Resuspended	  cell	  pellets	  were	  then	  stored	  in	  a	  -­‐80°C	  freezer.	  	  Cell	  pellets	  
were	  thawed	  in	  an	  ice	  water	  bath	  and	  disrupted	  by	  sonication	  in	  the	  presence	  of	  
2000-­‐4000	  units	  of	  Benzonase.	  	  The	  lysate	  was	  centrifuged	  at	  35,000	  rpm	  at	  4°C	  for	  
25	  minutes.	  	  The	  supernatant	  was	  pooled	  and	  filtered	  through	  a	  0.22-­‐micron	  syringe	  
filter.	  	  The	  filtered	  supernatant	  was	  then	  manually	  loaded	  onto	  a	  5	  mL	  HiTrap	  
nickel-­‐chelating	  column	  (Amersham	  Biosciences)	  using	  a	  peristaltic	  pump	  with	  a	  
flow	  rate	  of	  approximately	  1.0	  mL/minute.	  Immobilized	  metal	  affinity	  
chromatography	  (IMAC)	  and	  size	  exclusion	  chromatography	  (SEC)	  were	  
accomplished	  using	  an	  AKTA	  FPLC	  apparatus.	  Elution	  of	  the	  N-­‐terminal	  His6-­‐tagged	  
hKGA124-­‐551	  was	  accomplished	  by	  using	  an	  increasing	  gradient	  of	  75	  mM	  to	  400	  mM	  
imidazole	  in	  300	  mM	  KCl,	  10	  mM	  Tris-­‐Cl,	  pH	  8.0,	  10	  mM	  potassium	  phosphate,	  10%	  
glycerol	  (v/v),	  and	  0.5	  mM	  TCEP.	  	  Fractions	  were	  collected	  in	  3.0	  mL	  volumes	  and	  
assayed	  using	  10%	  SDS-­‐PAGE.	  	  The	  fraction	  containing	  the	  hKGA124-­‐551	  was	  loaded	  
manually	  onto	  a	  S200	  Superdex™	  16/60	  gel	  filtration	  column	  and	  eluted	  using	  300	  
mM	  KCl,	  10	  mM	  Tris	  pH	  8.0,	  100	  mM	  potassium	  phosphate,	  10%	  glycerol	  (v/v),	  and	  
0.5	  mM	  TCEP	  at	  a	  flow	  rate	  of	  1.0	  mL/min.	  	  Fractions	  were	  collected	  in	  3.0	  mL	  
volumes	  and	  assayed	  by	  10%	  SDS-­‐PAGE.	  	  Purified	  recombinant	  protein	  was	  stored	  
in	  15	  mL	  falcon	  tubes	  at	  4°C.	  	  Fractions	  were	  collected	  throughout	  the	  expression	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and	  purification	  to	  assess	  the	  enrichment	  and	  recovery	  of	  the	  hKGA124-­‐551.	  	  The	  
activity	  and	  specific	  activity	  of	  the	  lysate,	  supernatant,	  and	  purified	  fraction	  was	  
measured	  using	  a	  modified	  version	  of	  the	  two-­‐step	  kinetic	  assay	  describe	  previously	  
(13).	  	  	  
	  
Kinetic	  Assays	  
hKGA124-­‐551	  activity	  was	  determined	  using	  a	  two-­‐step	  assay	  that	  was	  performed	  
using	  96-­‐well	  plates	  in	  a	  final	  volume	  of	  227	  µL	  per	  well	  (7).	  	  Each	  well	  contained	  10	  
µL	  of	  2X	  stock	  assay	  mix	  #1	  containing	  300	  mM	  potassium	  phosphate,	  0.4	  mM	  EDTA,	  
100	  mM	  tris	  acetate,	  pH	  8.6,	  and	  10	  µL	  of	  40	  mM	  glutamine.	  	  The	  assay	  was	  started	  
by	  adding	  5	  µL	  of	  an	  appropriate	  dilution	  of	  the	  recombinant	  hKGA124-­‐551	  to	  20	  µL	  of	  
the	  complete	  assay	  mix.	  	  The	  reaction	  was	  incubated	  for	  10	  minutes	  in	  a	  37°C	  
incubator	  and	  stopped	  by	  the	  addition	  of	  2	  µL	  of	  3N	  HCl.	  	  Next,	  200	  µL	  of	  assay	  mix	  
#2	  containing	  0.4	  mg/mL	  bovine	  liver	  glutamate	  dehydrongenase	  (Sigma),	  80	  mM	  
tris	  acetate,	  pH	  9.4,	  200	  mM	  hydrazine,	  2.5	  mM	  ADP,	  and	  0.2	  mM	  NAD+	  was	  added.	  	  
Reaction	  samples	  were	  incubated	  for	  35	  minutes	  at	  room	  temperature.	  	  Absorbance	  
at	  340	  nm	  was	  read	  using	  a	  Wallac	  Victor3V	  plate	  reader	  (PerkinElmer).	  	  Each	  
sample	  absorbance	  was	  measured	  against	  a	  blank	  in	  which	  the	  3N	  HCl	  was	  added	  
immediately	  before	  the	  addition	  of	  hKGA124-­‐551.	  In	  the	  first	  reaction	  glutamine	  is	  
converted	  into	  glutamate	  and	  an	  ammonium	  ion.	  	  The	  addition	  of	  3	  N	  HCl	  denatures	  
the	  glutaminase	  before	  the	  secondary	  reaction	  mixture	  is	  added.	  	  In	  the	  second	  
reaction,	  bovine	  liver	  glutamate	  dehydrogenase	  catalytically	  converts	  glutamate,	  
from	  the	  first	  reaction,	  into	  α-­‐ketoglutarate	  producing	  an	  equivalent	  amount	  of	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NADH	  per	  molecule	  of	  glutamate.	  	  Hydrazine	  reacts	  with	  α-­‐ketoglutarate,	  forming	  a	  
hydrazide	  to	  ensure	  that	  the	  reaction	  proceeds	  to	  completion.	  To	  study	  the	  
inhibition	  of	  hKGA124-­‐551,	  a	  GA	  inhibitor	  (Gilford	  Pharmaceuticals),	  bis-­‐2-­‐	  (5-­‐
phenylactamido-­‐1,	  2,4-­‐thiadiazol-­‐2-­‐yl)	  ethyl	  sulfide	  (BPTES),	  is	  added	  to	  the	  
primary	  reaction	  in	  a	  1	  µL	  volume	  to	  yield	  a	  final	  concentration	  of	  0.1	  µM,	  0.3	  µM,	  
0.6	  µM,	  1.0	  µM,	  and	  2.0	  µM.	  	  Since	  BPTES	  is	  dissolved	  in	  DMSO,	  a	  DMSO	  control	  was	  
performed	  by	  adding	  1	  µL	  of	  DMSO	  to	  reaction	  mixture	  before	  the	  addition	  of	  
hKGA124-­‐551.	  	  Activity	  (units/mL)	  and	  specific	  activity	  (units/mg)	  were	  calculated	  
using	  Excel	  software	  (Microsoft).	  	  Data	  analysis	  to	  determine	  the	  kinetic	  constants,	  
Km	  and	  Vmax,	  were	  performed	  using	  KaleidaGraph	  software	  (Synergy	  Software)	  to	  fit	  
the	  Michaelis-­‐Menten	  equation:	  
	  
	  
where	  the	  [Gln]	  is	  the	  substrate	  concentration	  in	  mM.	  	  Glutamine	  saturation	  profiles	  
were	  conducted	  with	  five	  replicates	  of	  each	  concentration	  between	  0.5	  mM	  to	  80	  
mM	  glutamine.	  To	  study	  the	  inhibition	  of	  hKGA124-­‐551	  by	  BPTES,	  glutamine	  
saturation	  profiles	  were	  performed	  in	  the	  presence	  of	  DMSO,	  0.1	  µM,	  0.3	  µM,	  0.6	  µM,	  
and	  1.0	  µM	  BPTES.	  	  	  To	  determine	  the	  Ki	  for	  BPTES,	  the	  apparent	  Vmax	  and	  apparent	  
Km	  were	  plotted	  against	  the	  concentration	  of	  BPTES	  using	  KaleidaGraph	  software	  to	  
fit	  the	  equations:	  
	  
	  
Vmax	  •	  [Gln]	  









where	  the	  [I]	  is	  equal	  to	  the	  concentration	  of	  BPTES.	  	  	  
	  
Phosphate	  activation	  profiles	  were	  completed	  in	  replicates	  of	  five	  using	  a	  range	  
of	  phosphate	  concentrations	  (0.5	  mM	  to	  150	  mM)	  in	  the	  presence	  of	  1	  µL	  DMSO,	  0.5	  
µM,	  1.0	  µM,	  3.0	  µM,	  and	  10	  µM	  BPTES.	  	  The	  Hill	  coefficient	  and	  K0.5	  were	  determined	  
using	  KalidaGraph	  software	  to	  perform	  a	  non-­‐linear	  least	  squares	  fit	  to	  the	  Hill	  
equation	  
	  
vo/Vmax	  =	  [P]h/(K0.5	  +	  [P]h)	  	  
	  
where	  vo/Vmax	  is	  the	  fractional	  saturation	  of	  hKGA124-­‐551	  with	  phosphate,	  h	  is	  the	  
Hill	  coefficient,	  K0.5	  is	  the	  dissociation	  constant,	  and	  [P]	  is	  the	  concentration	  of	  
phosphate.	  
	  
Size	  Exclusion	  Gel	  Filtration	  Chromatography	  
Gel	  filtration	  chromatography	  was	  performed	  using	  a	  15-­‐mL	  Bio-­‐Silect	  SEC	  250	  
column	  with	  an	  AKTA	  FPLC	  system	  at	  4°C	  (7).	  	  A	  80-­‐µL	  sample	  containing	  1.0	  
mg/mL,	  roughly	  20	  µM,	  of	  recombinant	  hKGA124-­‐551	  was	  applied	  to	  the	  SEC	  column	  
Apparent	  Vmax	  =	  	  	  	  Vmax	  
	   	   	  	  	  	  	  	  	  (1+	  [I]/Ki)	  
Apparent	  Km	  =	  	  	  	  	  	  	  Km	  
	   	   	  	  	  (1+	  [I]/Ki)	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that	  was	  pre-­‐equilibrated	  in	  300	  mM	  KCl,	  10	  mM	  tris-­‐Cl,	  pH	  8.0,	  10%	  glycerol	  (v/v),	  
and	  0.5	  mM	  TCEP	  with	  varying	  concentrations	  of	  potassium	  phosphate.	  	  hKGA124-­‐551	  
was	  concentrated	  in	  a	  20	  mL	  Viaspin	  3.0	  kDa	  MW	  cut-­‐off	  concentrator	  by	  
centrifuging	  in	  a	  swinging	  bucket	  rotor	  (Beckman)	  at	  1207	  x	  g	  at	  4°C.	  	  Concentrated	  
samples	  where	  dialyzed	  against	  SEC	  buffer	  containing	  0	  mM	  potassium	  and	  100	  mM	  
potassium	  phosphate	  (Sigma)	  for	  3	  to	  5	  hours	  at	  4°C.	  	  Dialyzed	  samples	  where	  
loaded	  onto	  the	  Bio-­‐Silect	  250	  column	  in	  80	  uL	  volumes	  and	  the	  elution	  profile	  was	  
determined	  by	  measuring	  the	  absorbance	  at	  230	  nm.	  	  	  
Bio-­‐Rad	  gel	  filtration	  standards	  where	  used	  to	  calibrate	  the	  gel	  filtration	  column	  
to	  assess	  apparent	  molecular	  weights.	  	  The	  standard	  contains	  bovine	  thyroglobulin	  
(670,000	  Da),	  bovine	  γ-­‐globulin	  (158,000	  Da),	  chicken	  ovalbumin	  (44,000	  Da),	  horse	  
myoglobin	  (17,000	  Da),	  and	  vitamin	  B12	  (1,350	  Da).	  	  The	  mixture	  was	  rehydrated	  
using	  water	  and	  loaded	  onto	  the	  column	  using	  a	  volume	  of	  ≤	  1%	  of	  the	  total	  column	  
volume.	  	  The	  elution	  of	  the	  standards	  was	  tracked	  using	  absorbance	  at	  230	  nm	  and	  
280	  nm.	  
	  
Size	  Exclusion	  Chromatography-­Multi	  Angle	  Light	  Scattering	  (SEC-­MALS)	  
Light	  scattering	  experiments	  were	  performed	  using	  Wyatt	  Technologies	  
DAWN®	  HELEOS™	  II	  in	  tandem	  with	  Optilab®	  T-­‐rEX	  dectors	  coupled	  to	  an	  AKTA	  
FPLC	  system	  connected	  to	  S200	  Superdex™	  10/30	  gel	  filtration	  column.	  	  The	  SEC	  
column	  was	  equilibrated	  in	  SEC-­‐MALS	  buffer	  containing	  5	  mM	  L-­‐arginine,	  300	  mM	  
KCl,	  10	  mM	  Tris	  pH	  8.0,	  2%	  glycerol	  (v/v),	  and	  0.5	  mM	  TCEP	  with	  either	  0	  mM	  or	  
150	  mM	  phosphate.	  	  Each	  SEC-­‐MALS	  buffer	  was	  filtered	  sequentially	  using	  a	  0.22-­‐
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micron	  filter	  and	  0.10-­‐micron	  filter.	  	  Recombinant	  hKGA124-­‐551	  was	  purified	  as	  
discussed	  above	  with	  the	  addition	  of	  a	  third	  chromatography	  step.	  	  Ion	  exchange	  
chromatography	  was	  performed	  after	  the	  nickel	  IMAC	  purification	  step.	  	  Fractions	  
containing	  sample	  where	  pooled	  from	  the	  nickel	  purification	  and	  diluted	  10-­‐fold	  in	  
Q-­‐column	  buffer	  A	  containing	  10	  mM	  Tris	  pH	  8.0,	  10%	  glycerol	  (v/v),	  0.25	  mM	  TCEP,	  
and	  10	  mM	  potassium	  phosphate.	  	  The	  sample	  was	  loaded	  manually,	  using	  a	  
peristaltic	  pump	  at	  a	  flow	  rate	  of	  2.0	  mL/min,	  onto	  a	  Hi-­‐Trap	  Q	  (GE	  Healthcare)	  ion	  
exchange	  column	  equilibrated	  in	  Q-­‐column	  buffer	  A.	  	  The	  column	  was	  then	  
connected	  to	  an	  AKTA	  FPLC	  and	  the	  target	  protein	  was	  eluted	  off	  the	  column	  using	  
an	  increasing	  KCl	  gradient.	  	  Fractions	  were	  collected	  in	  5	  mL	  while	  a	  chromatogram	  
tracked	  absorbance	  of	  the	  eluant	  at	  280	  nm.	  	  Samples	  containing	  hKGA124-­‐551	  were	  
assayed	  using	  10%	  SDS-­‐PAGE	  and	  then	  concentrated	  into	  two	  separate	  fractions	  of	  
less	  than	  3.0	  mL	  and	  loaded	  onto	  S200	  16/60	  gel	  filtration	  column	  as	  described	  
above.	  	  Due	  to	  the	  instability	  of	  hKGA124-­‐551	  at	  high	  concentrations,	  the	  S200	  16/60	  
gel	  filtration	  was	  performed	  twice	  to	  ensure	  greater	  stability	  and	  lower	  
concentrations	  of	  hKGA124-­‐551	  per	  fraction.	  	  Fractions	  were	  assayed	  by	  10%	  SDS-­‐
PAGE	  and	  then	  pooled	  for	  concentration.	  	  Purified	  hKGA124-­‐551	  was	  concentrated	  as	  
describe	  above	  to	  roughly	  1.0	  mg/mL.	  	  The	  concentrated	  samples	  were	  loaded	  onto	  
the	  SEC-­‐MALS	  AKTA	  FPLC	  system	  with	  and	  without	  2.0	  µM	  BPTES	  in	  0	  mM	  
phosphate	  and	  150	  mM	  phosphate	  at	  a	  flow	  rate	  of	  0.3	  mL/min.	  	  A	  chromatogram	  
tracked	  the	  absorbance	  of	  each	  sample	  at	  280	  nm	  or	  230	  nm.	  	  Analysis	  of	  SEC-­‐MALS	  




I	  initially	  planned	  to	  characterize	  the	  hKGA221-­‐532	  form	  of	  glutaminase.	  	  However,	  
expression	  and	  purification	  of	  recombinant	  hKGA221-­‐532	  was	  problematic.	  Analysis	  of	  
the	  expression	  by	  SDS-­‐PAGE	  indicates	  that	  most	  of	  the	  enzyme	  remains	  insoluble	  
due	  to	  the	  presence	  of	  a	  very	  intense	  band	  in	  the	  pellet	  fraction	  (data	  not	  shown).	  	  
The	  small	  yield	  that	  is	  produced	  from	  purification	  does	  not	  appear	  to	  be	  stable	  in	  
solution.	  	  It	  rapidly	  lost	  activity	  and	  precipitated	  out	  of	  solution.	  	  Buffer	  changes	  and	  
pH	  changes	  have	  not	  produced	  soluble	  enzyme	  long	  enough	  to	  study	  its	  kinetic	  
behavior.	  	  Further	  study	  found	  that	  there	  was	  a	  C-­‐terminal	  degradation	  of	  hKGA221-­‐
532	  during	  expression	  and	  purification.	  	  This	  was	  confirmed	  by	  western	  blot	  (data	  
not	  shown)	  as	  two	  bands	  reacted	  with	  the	  GA	  antibody	  just	  below	  the	  50-­‐kDa	  
marker.	  	  In	  attempt	  to	  alleviate	  these	  problems,	  the	  plasmid	  used	  by	  the	  SGC	  to	  
determine	  the	  crystal	  structure	  was	  obtained.	  	  This	  hKGA	  construct	  also	  contained	  
amino	  acids	  221-­‐532	  but	  contains	  an	  N-­‐terminal	  proteolytic	  cleavage	  sequence	  that	  
can	  be	  used	  to	  remove	  the	  His6-­‐tag	  from	  the	  construct.	  	  Expression	  and	  purification	  
of	  this	  newly	  obtained	  construct	  was	  also	  problematic.	  	  The	  hKGA221-­‐532	  construct	  
was	  soluble	  in	  very	  small	  amounts	  and	  precipitated	  from	  solution	  prior	  to	  
purification	  attempts.	  	  As	  seen	  with	  the	  previous	  construct,	  it	  was	  difficult	  to	  
determine	  enzymatic	  activity	  as	  the	  sample	  precipitated	  out	  of	  solution.	  	  Due	  to	  






Recombinant	  protein	  expression	  and	  purification	  
The	  hKGA124-­‐551	  pET-­‐15b	  plasmid	  was	  transformed	  into	  the	  BL-­‐21	  (DE3)	  strain	  
of	  E.	  coli	  and	  plated	  on	  LB	  media	  containing	  100	  µg/mL	  ampicillin	  and	  34	  µg/mL	  
chloramphenicol.	  A	  1-­‐mL	  aliquot	  of	  a	  5-­‐mL	  overnight	  culture	  was	  added	  to	  each	  of	  
the	  two	  1-­‐L	  flasks	  of	  2xYT	  growth	  media.	  	  The	  uninduced	  culture	  was	  grown	  at	  37°C	  
until	  the	  O.D.600	  reached	  1.0	  to	  1.5.	  	  The	  culture	  was	  then	  cooled	  to	  18°C	  before	  
being	  induced	  with	  0.5	  mM	  IPTG.	  The	  quality	  of	  induction	  can	  be	  seen	  in	  Figure	  6.	  	  
The	  first	  lane	  shows	  the	  uninduced	  sample	  where	  there	  is	  minimal	  band	  intensity	  
near	  the	  50-­‐kDa	  marker.	  	  In	  the	  induced	  sample	  (lane	  two),	  there	  is	  a	  very	  intense	  
band	  just	  below	  the	  50-­‐kDa	  marker.	  	  This	  shows	  that	  there	  is	  very	  little	  leaky	  
transcription	  of	  the	  transformed	  plasmid	  and	  that	  the	  target	  protein	  is	  effectively	  
induced.	  	  Comparison	  of	  the	  pellet	  fraction	  and	  supernatant	  fractions	  indicate	  that	  
more	  than	  half	  of	  the	  protein	  remains	  soluble	  and	  that	  sonication	  is	  an	  adequate	  cell	  
disruption	  method.	  	  The	  supernatant	  was	  subsequently	  filtered	  and	  manually	  
loaded	  onto	  a	  5-­‐mL	  nickel	  column	  equilibrated	  in	  buffer	  A	  (300	  mM	  KCl,	  10	  mM	  tris-­‐
Cl,	  pH	  8.0,	  10	  mM	  potassium	  phosphate,	  10%	  glycerol	  (v/v),	  and	  0.5	  mM	  TCEP).	  	  The	  
His6-­‐tagged	  hKGA124-­‐551	  was	  eluted	  from	  the	  column	  using	  an	  increasing	  imidazole	  
gradient.	  	  Column	  fractions	  24-­‐26	  (Figures	  7,	  8)	  contain	  an	  intense	  band	  near	  the	  
50-­‐kDa	  marker	  that	  correlates	  with	  the	  elution	  profile	  of	  the	  nickel	  column	  (Figure	  
7).	  	  The	  column	  eluant	  was	  collected	  in	  3-­‐mL	  fractions	  and	  no	  further	  concentration	  
was	  required.	  	  Column	  fraction	  25	  was	  then	  manually	  loaded	  onto	  a	  Superdex	  S200	  











Figure	  6	  Expression	  analysis	  of	  hKGA124-­551	  construct	  
10%	  SDS-­‐PAGE	  was	  performed	  to	  track	  the	  expression	  and	  purification	  of	  
hKGA124-­‐551.	  	  The	  un-­‐induced	  cell	  culture	  (Un)	  was	  induced	  using	  0.5	  mM	  IPTG	  
(In)	  as	  shown	  in	  lanes	  2	  and	  3	  respectively.	  	  The	  solubility	  of	  hKGA128-­‐532	  in	  lysis	  
buffer	  is	  represented	  by	  the	  lysate	  (Lys)	  (lane	  4),	  pellet	  (P)	  (lane	  5),	  and	  
supernatant	  (S)	  (lane	  6)	  fractions.	  	  The	  supernatant	  was	  then	  manually	  loaded	  
onto	  5-­‐mL	  nickel	  column	  and	  the	  flow	  through	  (FT)	  was	  collected	  (lane	  7).	  	  
	  




	   	  
	  
	  
Figure	  7.	  Elution	  Profile	  of	  hKGA	  124-­551	  from	  a	  5-­mL	  nickel	  column	  
The	  nickel	  column	  was	  equilibrated	  in	  buffer	  A	  and	  the	  cell	  supernatant	  was	  
manually	  loaded	  on	  the	  column.	  	  The	  column	  was	  then	  placed	  onto	  the	  AKTA	  
FPLC	  system	  where	  an	  increasing	  imidazole	  gradient	  (green	  line)	  was	  used	  to	  
elute	  off	  the	  his6-­‐tagged	  glutaminase	  in	  3-­‐mL	  fractions.	  	  1%	  to	  7.5	  %	  buffer	  B	  (75	  
mM	  imidazole)	  was	  run	  for	  20	  column	  volumes	  until	  the	  A280	  leveled	  off	  near	  
zero.	  	  The	  concentration	  of	  imidazole	  was	  then	  increased	  to	  400	  mM	  (40%	  buffer	  
B)	  to	  elute	  the	  target	  protein	  in	  one	  step.	  	  Once	  the	  A280	  	  (blue	  line)	  leveled	  off	  
100%	  buffer	  B	  (1M	  imidazole)	  was	  run	  for	  5	  column	  volumes	  to	  remove	  any	  
proteins	  still	  bound	  to	  the	  nickel	  resin.	  	  From	  this	  chromatogram	  samples	  where	  









Figure	  8	  IMAC	  	  purification	  by	  nickel	  affinity	  chromatography	  
Analysis	  of	  IMAC	  purification	  by	  10%	  SDS-­‐PAGE	  shows	  that	  His6-­‐tagged	  hKGA124-­‐
551	  binds	  with	  high	  affinity	  to	  the	  nickel	  column.	  	  Fraction	  numbers	  2,	  3,	  6,	  8,	  and	  
9	  show	  column	  fractions	  containing	  protein	  contaminates	  eluted	  by	  10	  mM	  to	  75	  
mM	  imidazole.	  	  Column	  fraction	  24-­‐26	  (lanes	  7-­‐9)	  show	  how	  effective	  the	  elution	  
of	  the	  target	  protein	  was	  completed	  in	  one	  step	  at	  400	  mM	  imidazole.	  	  Column	  
fraction	  25	  was	  manually	  loaded	  onto	  a	  pre-­‐equilibrated	  S200	  16/60	  size	  
exclusion	  column	  for	  further	  purification.	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100	  mM	  potassium	  phosphate,	  10%	  glycerol	  (v/v),	  and	  0.5	  mM	  TCEP).	  	  The	  
fractions	  were	  collected	  in	  3-­‐mL	  volumes	  at	  a	  flow	  rate	  of	  1.0	  mL/minute.	  	  The	  gel	  
filtration	  purification	  was	  successful	  as	  seen	  in	  column	  fractions	  20-­‐24	  (Figures	  9,	  
10)	  where	  there	  is	  an	  intense	  band	  just	  below	  the	  50-­‐kDa	  marker.	  	  Furthermore,	  
when	  comparing	  Figure	  8	  to	  Figure	  10	  there	  is	  an	  apparent	  removal	  of	  
contaminating	  bands	  indicating	  that	  gel	  filtration	  is	  an	  effective	  chromatography	  
step	  for	  the	  further	  purification	  of	  hKGA124-­‐551.	  	  SDS-­‐PAGE	  analysis	  correlates	  well	  
with	  the	  gel	  filtration	  chromatogram	  as	  seen	  in	  both	  the	  nickel	  IMAC	  and	  SEC	  
purification	  steps	  (Figures	  7	  and	  9,	  respectively).	  	  Lastly,	  there	  is	  a	  broad	  peak	  and	  
significant	  tail	  in	  the	  gel	  filtration	  profile	  (Figure	  9	  and	  10)	  indicating	  that	  the	  




The	  activity	  of	  hKGA124-­‐551	  was	  tracked	  throughout	  the	  purification.	  	  As	  seen	  in	  
Table	  1,	  the	  specific	  activities	  between	  the	  lysate	  and	  supernatant	  fractions,	  8.4	  
U/mg	  and	  10	  U/mg	  respectively,	  were	  similar.	  	  The	  specific	  activity	  of	  the	  hKGA124-­‐
551	  recovered	  from	  the	  nickel	  column	  was	  increased	  60-­‐fold	  (590	  U/mg).	  	  The	  
purification	  was	  accomplished	  with	  a	  recovery	  of	  approximately	  20%	  of	  the	  total	  
activity	  expressed	  in	  the	  initial	  lysate.	  	  The	  specific	  activity	  of	  the	  purified	  hKGA124-­‐
551	  is	  similar	  to	  the	  specific	  activity	  of	  full-­‐length	  rKGA	  and	  a	  truncated	  version	  of	  the	  


























Figure	  9	  Gel	  filtration	  chromatogram	  of	  hKGA124-­551	  purification	  
hKGA	  128-­‐532	  was	  eluted	  at	  a	  flow	  rate	  of	  1.0	  mL/min	  and	  monitored	  
by	  A280	  (blue	  line)	  and	  A254	  (red	  line).	  The	  chromatogram	  shows	  a	  
very	  sharp	  peak	  corresponding	  to	  column	  fractions	  14	  and	  15.	  
Protein	  samples	  where	  collected	  from	  column	  fractions	  13-­‐16,	  19-­‐28,	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Figure	  10	  Purification	  analysis	  of	  hKGA124-­551	  using	  gel	  filtration	  
chromatography	  
Column	  fraction	  25	  from	  the	  nickel	  affinity	  chromatography	  was	  
manually	  loaded	  onto	  S200	  16/60	  Superdex	  column	  equilibrated	  in	  300	  
mM	  KCl,	  10	  mM	  Tris	  pH	  8.0,	  100	  mM	  potassium	  phosphate,	  10%	  glycerol	  
(v/v),	  and	  0.5	  mM	  TCEP	  at	  a	  flow	  rate	  of	  1.0	  mL/min.	  	  Fractions	  were	  
collected	  in	  3.0-­‐mL	  volumes	  and	  assayed	  by	  10%	  SDS-­‐PAGE.	  Column	  
fractions	  19	  through	  28	  contain	  the	  target	  protein	  indicated	  by	  the	  band	  
intensity	  just	  below	  the	  50-­‐kDa	  marker.	  	  Column	  fractions	  20-­‐24,	  which	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The	  activity	  of	  hKGA124-­‐551	  was	  monitored	  throughout	  the	  purification.	  The	  
activity	  (units/mL)	  and	  specific	  activity	  (units/mg)	  increase	  throughout	  the	  
purification	  as	  seen	  in	  columns	  2	  and	  6.	  	  The	  protein	  concentration	  was	  
assayed	  by	  the	  Bradford	  method	  (column	  4).	  	  The	  total	  protein	  (column	  5)	  
was	  calculated	  by	  multiplying	  the	  concentration	  by	  the	  total	  volume	  of	  the	  
sample	  (column	  1).	  	  The	  total	  activity	  (column	  3)	  was	  calculated	  by	  
multiplying	  the	  activity	  (column	  2)	  by	  the	  total	  volume	  of	  sample	  (column	  1).	  	  	  
The	  activity	  assay	  was	  performed	  using	  the	  method	  of	  Kenny,	  J.	  et	  al.	  2003	  
where	  the	  total	  volumes	  of	  the	  assay	  are	  larger	  and	  not	  run	  in	  a	  96-­‐well	  micro	  
plate.	  





To	  determine	  the	  kinetic	  properties	  and	  type	  of	  inhibition	  by	  BPTES,	  glutamine	  
saturation	  profiles	  were	  performed	  using	  DMSO	  or	  0.1,	  0.3,	  0.6,	  and	  1.0	  µM	  BPTES	  in	  
DMSO.	  	  Figure	  11	  shows	  the	  increase	  in	  hKGA124-­‐551	  specific	  activity	  with	  increasing	  
concentrations	  of	  glutamine	  at	  10	  mM	  or	  30	  mM	  phosphate.	  	  The	  data	  fit	  to	  a	  
hyperbolic	  saturation	  profile,	  and	  at	  each	  increasing	  concentration	  of	  BPTES	  the	  
specific	  activity	  was	  reduced.	  	  Figure	  11a	  shows	  glutamine	  saturation	  data	  in	  the	  
presence	  of	  BPTES	  at	  10	  mM	  phosphate,	  whereas	  Figure	  11b	  shows	  the	  glutamine	  
saturation	  data	  at	  30	  mM	  phosphate.	  	  The	  observed	  Km	  for	  hKGA	  124-­‐551	  in	  the	  
presence	  of	  DMSO	  at	  10	  mM	  phosphate	  was	  1.2	  mM	  ±	  0.2	  which	  was	  similar	  to	  the	  
Km	  of	  1.5	  mM	  ±	  0.13	  at	  30	  mM	  phosphate.	  	  In	  both	  phosphate	  concentrations	  the	  
observed	  Km	  and	  the	  observed	  Vmax	  decreased	  as	  the	  concentration	  of	  BPTES	  
increased.	  	  The	  data	  shows	  that	  there	  is	  a	  significant	  decrease	  in	  Vmax	  and	  a	  slight	  
decrease	  in	  Km	  indicative	  of	  uncompetitive	  inhibition	  or	  a	  mixed	  inhibition	  model.	  	  A	  
detailed	  determination	  of	  Km	  and	  Vmax	  values	  can	  be	  seen	  in	  Supplemental	  Table	  1	  in	  
Appendix	  1.	  This	  conclusion	  is	  better	  illustrated	  in	  the	  double	  reciprocal	  plots	  
(Figure	  12a	  and	  12b).	  	  When	  comparing	  the	  DMSO	  control	  to	  0.1	  µM	  BPTES	  at	  10	  
mM	  phosphate,	  the	  inhibition	  appears	  to	  be	  mixed	  non-­‐competitive	  inhibition	  
(Figure	  12a).	  	  However,	  at	  30	  mM	  phosphate	  and	  0.1	  µM	  BPTES	  the	  model	  of	  
inhibition	  appears	  to	  be	  uncompetitive	  (Figure	  12b).	  	  At	  higher	  concentrations	  of	  
BPTES,	  the	  inhibition	  profiles	  fit	  best	  to	  an	  uncompetitive	  model	  at	  both	  10	  and	  30	  
mM	  phosphate.	  	  Strict	  non-­‐competitive	  inhibition	  occurs	  when	  the	  inhibitor	  binds	  to	  
a	  site	  separate	  from	  the	  substrate	  binding	  site,	  resulting	  in	  a	  decrease	  of	  enzymatic	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turnover,	  while	  the	  Km	  remains	  unchanged.	  	  Uncompetitive	  inhibition	  occurs	  when	  
the	  inhibitor	  binds	  to	  the	  enzyme-­‐substrate	  complex	  and	  alters	  the	  Km	  and	  catalytic	  
activity	  to	  a	  similar	  extent.	  A	  mixed	  inhibition	  model	  occurs	  when	  the	  inhibitor	  can	  
bind	  free	  enzyme	  and	  enzyme-­‐substrate	  complex	  and	  produces	  differential	  effects	  
on	  the	  catalytic	  activity	  and	  the	  Km	  for	  substrate.	  	  For	  a	  strict	  non-­‐competitive	  
inhibition,	  all	  the	  lines	  of	  the	  double	  reciprocal	  plots	  should	  intercept	  on	  the	  x-­‐axis	  
indicating	  the	  Km	  remains	  unchanged,	  and	  each	  line	  should	  intercept	  the	  y-­‐axis	  at	  
higher	  values	  for	  higher	  inhibitor	  concentrations	  indicating	  the	  Vmax	  decreases.	  On	  
the	  other	  hand,	  typical	  uncompetitive	  inhibition	  should	  yield	  parallel	  lines	  on	  the	  
double	  reciprocal	  plot	  that	  intersect	  the	  x-­‐axis	  and	  y-­‐axis	  at	  different	  positions	  
indicating	  similar	  changes	  in	  both	  Vmax	  and	  Km.	  Double	  reciprocal	  plots	  of	  mixed	  
inhibition	  result	  in	  the	  lines	  intersecting	  before	  the	  y-­‐axis	  indicating	  differential	  
changes	  in	  both	  Vmax	  and	  Km.	  
The	  Ki	  for	  BPTES	  was	  determined	  at	  both	  10	  mM	  and	  30	  mM	  phosphate	  by	  
plotting	  the	  apparent	  Vmax	  and	  the	  apparent	  Km	  against	  the	  concentration	  of	  BPTES	  
(Figures	  13a	  and	  13b,	  respectively).	  	  At	  10	  mM	  phosphate	  the	  Ki	  determined	  by	  
plotting	  the	  apparent	  Vmax	  was	  0.14	  ±	  0.01	  µM,	  and	  by	  plotting	  the	  apparent	  Km	  the	  
Ki	  was	  0.21	  ±	  0.06	  µM.	  	  At	  30	  mM	  phosphate	  the	  Ki	  determined	  by	  plotting	  the	  
apparent	  Vmax	  was	  0.24	  ±	  0.03	  µM,	  and	  plotting	  the	  apparent	  Km	  the	  Ki	  was	  0.16	  ±	  
0.02	  µM.	  	  Large	  changes	  in	  Ki	  at	  either	  phosphate	  concentration	  would	  support	  a	  
mixed	  inhibition	  and	  non-­‐competitive	  inhibition	  model;	  however,	  the	  data	  indicate	  












Figure	  11	  Glutamine	  saturation	  profiles	  in	  the	  presence	  of	  BPTES	  
Glutamine	  saturation	  profiles	  were	  performed	  in	  10	  mM	  (panel	  A)	  and	  30	  
mM	  (panel	  B)	  phosphate	  with	  increasing	  concentrations	  of	  BPTES.	  	  The	  
data	  are	  plotted	  using	  KalidaGraph	  software	  and	  fit	  to	  the	  Michaelis-­‐
Menten	  equation	  using	  a	  non-­‐linear	  regression.	  	  The	  specific	  activity	  in	  
units/mg	  was	  plotted	  against	  the	  concentration	  of	  glutamine.	  	  Data	  are	  the	  



































Figure	  12	  Double-­reciprocal	  plots	  of	  hKGA124-­551	  activity	  
Lineweaver-­‐Burke	  double-­‐reciprocal	  plot	  transformations	  of	  the	  
glutamine	  saturation	  data	  were	  plotted	  for	  hKGA124-­‐551	  in	  the	  
presence	  of	  10	  mM	  phosphate	  (panel	  A)	  or	  in	  the	  presence	  of	  30	  
mM	  phosphate	  (panel	  B).	  	  Increasing	  concentrations	  of	  BPTES	  
was	  added	  from	  0.1	  µM	  to	  1.0	  µM.	  	  The	  lines	  represent	  a	  linear	  
curve	  fit	  of	  the	  reciprocal	  mean	  specific	  activity	  versus	  the	  


























Figure	  13	  Determination	  of	  Ki	  
The	  Ki	  for	  hKGA124-­‐551	  was	  determined	  by	  plotting	  both	  the	  apparent	  Vmax	  (panel	  A)	  
and	  apparent	  Km	  (panel	  B)	  versus	  the	  concentration	  of	  BPTES	  using	  KalidaGraph	  
software.	  	  In	  panel	  A	  the	  dashed	  blue	  line	  represents	  the	  apparent	  Vmax	  used	  to	  
calculate	  the	  Ki	  for	  BPTES	  at	  10	  mM	  phosphate	  (0.14	  µM	  ±	  0.01)	  and	  the	  dashed	  
green	  represents	  the	  apparent	  Km	  used	  to	  calculate	  the	  Ki	  for	  BPTES	  at	  10	  mM	  
phosphate	  (0.21	  µM	  ±	  0.06).	  	  In	  panel	  B	  the	  dashed	  blue	  line	  represents	  the	  Ki	  for	  30	  
mM	  phosphate	  (0.24	  µM	  ±	  0.03)	  calculated	  using	  the	  apparent	  Vmax	  and	  the	  dashed	  
green	  line	  line	  represents	  the	  Ki	  	  for	  30	  mM	  phosphate	  (0.16	  µM	  ±	  0.02)	  calculated	  





In	  the	  presence	  of	  10	  mM	  and	  30	  mM	  phosphate,	  the	  Ki	  remains	  nearly	  unchanged	  
and	  within	  their	  respective	  statistical	  standard	  error	  measurements.	  This	  
observation	  supports	  an	  uncompetitive	  model	  of	  inhibition	  over	  a	  mixed	  inhibition	  
model	  or	  non-­‐competitive	  inhibition	  model,	  because	  changes	  in	  BPTES	  produce	  
equivalent	  effects	  on	  the	  apparent	  Km	  and	  the	  apparent	  Vmax.	  	  The	  data	  clearly	  
exclude	  competitive	  and	  strict	  non-­‐competitive	  models	  of	  inhibition.	  	  However,	  the	  
data	  is	  not	  sufficient	  to	  clearly	  discriminate	  between	  an	  uncompetitive	  and	  mixed	  
inhibition	  model	  at	  low	  concentrations	  of	  phosphate,	  and	  it	  appears	  that	  the	  
mechanism	  of	  inhibition	  may	  be	  dependent	  upon	  the	  phosphate	  concentration.	  	  It	  is	  
clearly	  evident	  that	  in	  the	  30	  mM	  phosphate	  double-­‐reciprocal	  plot,	  the	  mechanism	  
of	  inhibition	  is	  strictly	  uncompetitive.	  	  	  
Phosphate	  activation	  profiles	  were	  performed	  in	  the	  presence	  of	  20	  mM	  
glutamine	  in	  the	  absence	  or	  presence	  of	  BPTES	  (Figure	  14).	  	  The	  specific	  activity	  of	  
hKGA124-­‐551	  increased	  as	  the	  concentration	  of	  phosphate	  increased.	  	  As	  the	  
concentration	  of	  BPTES	  increased	  the	  overall	  specific	  activity	  of	  hKGA124-­‐551	  
decreased.	  	  However,	  when	  the	  data	  were	  fit	  to	  the	  Hill	  equation	  using	  KalidaGraph	  
software,	  the	  overall	  profiles	  appear	  to	  be	  hyperbolic	  and	  the	  saturation	  profiles	  
exhibit	  a	  slight	  cooperativity	  (Table	  2)	  as	  previously	  observed	  with	  other	  
mammalian	  constructs	  (7).	  	  The	  K0.5	  values	  for	  phosphate	  increased	  significantly	  in	  
the	  presence	  of	  BPTES	  suggesting	  that	  phosphate	  and	  BPTES	  compete	  for	  binding	  to	  
hKGA124-­‐551.	  	  The	  Hill	  coefficient	  also	  increased	  as	  the	  concentration	  of	  BPTES	  
increased.	  This	  is	  evident	  in	  the	  activation	  profile	  (Figure	  14)	  where	  the	  10	  µM	  





















Figure	  14	  Phosphate	  activation	  profile	  of	  hKGA124-­551	  
Phosphate	  activation	  profiles	  where	  produced	  in	  the	  absence	  and	  presence	  of	  BPTES	  
over	  a	  range	  of	  phosphate	  concentrations	  (x-­‐axis).	  	  The	  y-­‐axis	  is	  the	  specific	  activity	  
of	  hKGA124-­‐551	  in	  the	  presence	  of	  the	  DMSO	  control	  at	  increasing	  concentrations	  of	  
BPTES.	  	  The	  data	  are	  the	  ±	  standard	  error	  of	  five	  measurements	  at	  each	  phosphate	  



























Sample	  	   K0.5	  (mM)	  	   Vmax	  	   Hill	  Coefficient	  	  
DMSO	  	   56	  ±	  16	  	   38.0	  ±	  1.8	  	   1.3	  ±	  0.1	  	  
0.5	  μM	  BPTES	  	   180	  ±	  60	  	   29	  .0±	  1.7	  	   1.4	  ±	  0.1	  	  
1.0	  μM	  BPTES	  	   500	  ±	  300	   21.0	  ±	  1.5	  	   1.6	  ±	  0.2	  	  
3.0	  μM	  BPTES	  	   1000	  ±	  500	  	   21.0	  ±	  1.7	  	   1.6	  ±	  0.2	  	  
10	  μM	  BPTES	  	   3000	  ±	  2000	  	   9.0	  ±	  0.3	  	   2.2	  ±	  0.2	  	  
	  





The	  overall	  activity	  for	  each	  concentration	  of	  BPTES	  increased	  as	  the	  concentration	  
of	  phosphate	  increased	  indicating	  increasing	  amounts	  of	  phosphate	  increase	  the	  
Vmax.	  	  Figure	  14	  clearly	  depicts	  the	  decrease	  in	  Vmax.	  	  As	  the	  inhibitor	  concentration	  is	  
increased,	  the	  hyperbolic	  curves	  plateau	  at	  lower	  specific	  activities.	  
	  
Gel	  Filtration	  Chromatography	  
Gel	  filtration	  chromatography	  was	  performed	  using	  concentrated	  hKGA124-­‐551	  in	  
the	  absence	  and	  presence	  of	  BPTES	  at	  0	  mM	  and	  100	  mM	  phosphate	  (Figure	  15a	  
and	  15b).	  	  At	  0	  mM	  phosphate,	  in	  the	  absence	  of	  BPTES,	  the	  sample	  has	  a	  longer	  
retention	  volume.	  	  The	  hKGA124-­‐551	  elutes	  from	  the	  column	  with	  a	  shorter	  retention	  
time	  in	  the	  presence	  of	  2	  µM	  and	  10	  µM	  BPTES	  (Figure	  15a).	  	  Comparing	  Figure	  15a	  
to	  15b	  shows	  that	  100	  mM	  phosphate	  does	  not	  shift	  the	  elution	  profile	  in	  the	  
absence	  of	  BPTES	  to	  the	  left	  decreasing	  the	  retention	  volume.	  	  In	  the	  presence	  of	  
100	  mM	  phosphate,	  the	  addition	  of	  2	  µM	  or	  10	  µM	  BPTES	  produced	  a	  shift	  in	  the	  
elution	  profiles,	  similar	  to	  the	  elution	  profiles	  in	  the	  absence	  of	  phosphate.	  
The	  apparent	  molecular	  weight	  of	  the	  hKGA124-­‐551	  was	  determined	  by	  calibrating	  the	  
Bio	  Silect	  250	  column	  with	  Bio	  Rad	  gel	  filtration	  standards.	  	  Plotting	  the	  elution	  
volume	  on	  the	  y-­‐axis	  and	  the	  log	  molecular	  weight	  on	  the	  x-­‐axis,	  as	  seen	  in	  Figure	  16,	  
generated	  a	  linear	  standard	  curve	  fit.	  	  From	  the	  standard	  curve	  the	  molecular	  
weights	  of	  hKGA124-­‐551	  were	  calculated.	  	  In	  the	  absence	  of	  phosphate	  and	  BPTES	  the	  
apparent	  molecular	  weight	  was	  103-­‐kDa	  and	  in	  the	  presence	  of	  100	  mM	  phosphate	  
the	  apparent	  molecular	  weight	  was	  124-­‐kDa.	  	  As	  the	  concentration	  of	  BPTES	  
increased	  so	  did	  the	  molecular	  weights	  in	  both	  the	  absence	  and	  presence	  of	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phosphate.	  	  The	  apparent	  molecular	  weight	  at	  2	  µM	  and	  10	  µM	  BPTES	  in	  the	  
absence	  of	  phosphate	  was	  226-­‐kDa	  and	  241-­‐kDa,	  respectively.	  	  In	  the	  presence	  of	  
100	  mM	  phosphate	  the	  apparent	  molecular	  weight	  at	  2	  µM	  and	  10	  µM	  BPTES	  was	  	  
245-­‐kDa	  and	  284-­‐kDa.	  	  The	  calculated	  molecular	  weight	  of	  the	  hKGA124-­‐551	  monomer	  
is	  46-­‐kDa.	  These	  data	  suggest	  that	  in	  the	  absence	  or	  presence	  of	  phosphate,	  hKGA124-­‐
551	  exists	  in	  a	  dimer.	  	  However,	  when	  BPTES	  is	  added,	  the	  molecular	  weight	  shifts	  to	  
a	  tetramer	  and	  or	  higher	  oligomeric	  forms.	  	  	  	  	  
	  
Size	  Exclusion	  Chromatography-­Multi	  Angle	  Light	  Scattering	  
Multi-­‐angle	  light	  scattering	  experiments	  of	  hKGA124-­‐551	  did	  not	  produce	  quality	  
results.	  	  Light	  scattering	  at	  280	  nm	  in	  the	  absence	  of	  BPTES	  and	  in	  0	  mM	  phosphate	  
generated	  preliminary	  data	  of	  a	  100-­‐kDa	  species.	  	  The	  addition	  of	  the	  2	  µM	  BPTES,	  
at	  0	  mM	  phosphate,	  shifted	  the	  molecular	  weight	  to	  about	  a	  200-­‐kDa	  form;	  however,	  
both	  of	  these	  experiments	  had	  large	  errors,	  in	  their	  measurements	  (data	  not	  shown).	  	  
The	  chromatogram	  peaks	  did	  not	  have	  a	  strong	  signal	  at	  280	  nm,	  and	  the	  scattering	  
data	  was	  very	  broad.	  	  The	  addition	  of	  phosphate	  made	  data	  interpretation	  nearly	  
impossible,	  and	  did	  not	  produce	  reliable	  data.	  	  Multiple	  attempts	  of	  multi-­‐angle	  light	  
scattering	  where	  performed	  but	  accurate	  measurements	  could	  not	  be	  made.	  	  Some	  
additional	  experiments	  where	  performed	  at	  230	  nm	  but	  did	  not	  produce	  any	  signal	  
for	  the	  chromatogram	  or	  light	  scattering.	  	  Furthermore,	  concentrating	  hKGA124-­‐551	  to	  


























Figure	  15	  Gel	  filtration	  chromatography	  of	  hKGA124-­551	  
Gel	  filtration	  chromatography	  was	  conducted	  by	  adding	  80	  µL	  of	  
concentrated	  hKGA124-­‐551	  to	  a	  Bio	  Silect	  250-­‐5	  14	  mL	  column	  in	  0	  mM	  
(panel	  A)	  and	  100	  mM	  phosphate	  (panel	  B)	  with	  and	  without	  the	  presence	  
of	  BPTES.	  	  Samples	  where	  run	  at	  0.7	  mL/min	  and	  A230	  was	  tracked	  
throughout	  the	  elution.	  	  A230	  was	  plotted	  against	  elution	  volume	  using	  
KalidaGraph	  software.	  	  The	  black	  line	  represents	  0	  µM	  BPTES	  while	  the	  


















Figure	  16	  Gel	  filtration	  standard	  curve	  
A	  50-­‐uL	  sample	  of	  Bio	  Rad	  Gel	  Filtration	  Standards	  was	  injected	  onto	  a	  
Bio-­‐Silect	  250	  gel	  filtration	  column.	  	  An	  AKTA	  FPLC	  tracked	  the	  elution	  of	  
each	  molecule	  at	  A280	  nm	  and	  A230	  nm.	  	  The	  peak	  absorbance	  for	  each	  
molecule	  was	  used	  to	  plot	  the	  retention	  volume	  (y-­‐axis)	  against	  the	  log10	  
molecular	  weight	  (x-­‐axis).	  	  The	  data	  were	  plotted	  using	  KalidaGraph	  





The	  expression	  protocol	  for	  hKGA124-­‐551	  was	  performed	  using	  2-­‐6	  L	  of	  2xYT	  
media.	  	  To	  facilitate	  solubility	  and	  recovery	  of	  the	  recombinant	  protein,	  an	  O.D.600	  ≥	  
1.0	  was	  achieved	  prior	  to	  inducing	  with	  0.5	  mM	  IPTG,	  and	  the	  temperature	  was	  
lowered	  from	  37˚C	  to	  18˚C.	  	  Induction	  of	  the	  cell	  culture	  at	  18˚C	  with	  a	  high	  
concentration	  of	  cells	  and	  a	  lower	  concentration	  of	  IPTG	  led	  to	  more	  cells	  making	  
less	  target	  protein	  at	  a	  slower	  rate.	  	  	  These	  are	  distinct	  changes	  from	  previous	  
expression	  procedures	  performed	  with	  a	  truncated	  form	  of	  the	  rat	  isoform	  of	  
mitochondrial	  kidney	  type	  glutaminase	  (7).	  	  	  The	  expression	  protocol,	  adopted	  from	  
the	  Structural	  Genomics	  Consortium	  (SGC)	  allowed	  for	  an	  apparent	  increase	  in	  the	  
soluble	  protein	  fraction.	  However,	  a	  large	  portion	  of	  the	  target	  protein	  still	  resided	  
in	  the	  pellet	  fraction.	  	  Sonication	  was	  the	  only	  cell	  disruption	  technique	  used.	  	  Using	  
multiple	  sonication	  steps	  (4-­‐6	  times	  at	  high	  intensity)	  for	  1	  to	  2	  minutes,	  with	  the	  
sample	  placed	  on	  ice,	  resulted	  in	  adequate	  recovery	  of	  soluble	  protein.	  	  Other	  cell	  
disruption	  methods	  such	  as	  using	  a	  micro	  fluidizer	  were	  not	  tested	  to	  compare	  the	  
efficiencies	  of	  each	  technique.	  
The	  purification	  of	  hKGA124-­‐551	  followed	  the	  SGC	  protocol	  closely.	  However,	  it	  
was	  optimized	  for	  the	  larger	  construct	  of	  human	  mitochondrial	  kidney	  type	  
glutaminase	  that	  included	  97	  additional	  amino	  acids	  on	  the	  N-­‐terminus.	  The	  IMAC	  
purification	  step	  was	  very	  efficient	  and	  removed	  many	  contaminating	  proteins	  from	  
the	  supernatant.	  	  Increasing	  the	  imidazole	  concentration	  and	  eluting	  the	  protein	  
from	  the	  column	  in	  one	  step	  led	  to	  a	  very	  concentrated	  and	  cloudy	  solution	  of	  
hKGA124-­‐551.	  	  It	  might	  have	  increased	  our	  protein	  recovery	  if	  a	  linear	  gradient	  of	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imidazole	  was	  run	  during	  the	  purification	  to	  elute	  the	  hKGA124-­‐551	  over	  a	  narrow	  
range	  of	  imidazole	  concentrations.	  	  This	  could	  have	  led	  to	  the	  removal	  of	  more	  
contaminants,	  but	  less	  protein	  per	  fraction,	  increasing	  hKGA124-­‐551	  solubility.	  	  Gel	  
filtration	  chromatography	  acted	  as	  a	  buffer	  exchange	  to	  remove	  the	  high	  salt	  
concentration	  from	  the	  IMAC	  step	  and	  diluted	  the	  sample	  to	  <	  1.0	  mg/mL	  in	  each	  3-­‐
mL	  fraction.	  	  These	  samples	  were	  very	  pure	  and	  remained	  clear	  for	  about	  2	  to	  3	  
weeks	  at	  4°C.	  	  It	  was	  found	  that	  concentrating	  the	  hKGA124-­‐551	  to	  over	  1.0	  mg/mL	  
decreased	  the	  stability	  of	  the	  enzyme	  and	  forced	  it	  to	  precipitate	  from	  solution	  
rapidly.	  	  	  
The	  saturation	  data	  show	  similar	  results	  to	  the	  activities	  of	  the	  intact	  and	  
truncated	  forms	  of	  the	  rat	  isoforms	  of	  KGA.	  	  The	  presence	  of	  DMSO	  does	  have	  a	  
slight	  effect	  on	  the	  activity	  of	  the	  enzyme	  reducing	  the	  specific	  activity	  roughly	  20-­‐
30%	  (data	  not	  shown).	  	  However,	  as	  seen	  with	  the	  rat	  isoform,	  the	  presence	  of	  
BPTES	  in	  µM	  concentrations	  had	  significant	  impact	  on	  human	  KGA	  activity.	  	  When	  
the	  assay	  was	  run	  in	  10	  mM	  phosphate	  the	  Vmax	  for	  the	  DMSO	  control	  was	  8.8	  ±	  0.3	  
units/mg.	  	  In	  the	  presence	  of	  30	  mM	  phosphate	  the	  Vmax	  for	  the	  DMSO	  control	  was	  
23	  ±	  0.4	  units/mg.	  	  This	  suggests	  that	  phosphate	  still	  acts	  as	  a	  strong	  positive	  
allosteric	  regulator	  of	  hKGA124-­‐551.	  	  Similarly,	  the	  specific	  activity	  of	  hKGA124-­‐551	  in	  
the	  presence	  of	  BPTES	  at	  30	  mM	  phosphate	  was	  always	  larger	  when	  compared	  to	  
the	  assay	  performed	  in	  the	  presence	  of	  10	  mM	  phosphate.	  	  The	  microtiter	  plate	  
assay	  allowed	  for	  five	  replicate	  samples	  at	  each	  concentration	  of	  glutamine.	  	  The	  
data	  showed	  that	  maximal	  enzyme	  velocity,	  or	  Vmax,	  was	  achieved	  in	  the	  presence	  of	  
20	  mM	  glutamine.	  	  The	  original	  microtiter	  plate	  assays	  were	  performed	  using	  0.5	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mM	  to	  80	  mM	  glutamine	  range	  and	  were	  saturated	  above	  20	  mM	  glutamine.	  	  The	  
reported	  data	  includes	  all	  glutamine	  data	  points.	  	  As	  seen	  in	  Supplemental	  Table	  1,	  
the	  glutamine	  saturation	  profiles	  in	  both	  the	  10	  and	  30	  mM	  phosphate	  solutions	  
where	  curve	  fit	  differently	  to	  address	  the	  statistical	  significance	  and	  reproducibility	  
and	  reliability	  of	  the	  data.	  	  The	  Supplemental	  Table	  shows	  that	  when	  each	  individual	  
data	  point,	  the	  mean	  data	  not	  weighted,	  and	  the	  mean	  data	  weighted	  by	  its	  standard	  
error	  generate	  nearly	  identical	  Km	  and	  Vmax	  values.	  	  This	  observation	  not	  only	  
suggests	  that	  the	  modified	  activity	  assay	  is	  accurate	  and	  precise,	  but	  is	  reproducible.	  	  	  
As	  previously	  mentioned,	  the	  Vmax	  for	  hKGA124-­‐551	  in	  the	  presence	  of	  BPTES	  
decreased.	  Similarly,	  the	  Km	  decreased	  as	  the	  concentration	  of	  BPTES	  increased.	  	  The	  
saturation	  data	  was	  then	  plotted	  as	  Lineweaver-­‐Burk	  double	  reciprocal	  plots.	  	  The	  
transformed	  data	  sets	  indicated	  that	  the	  model	  of	  inhibition	  by	  BPTES	  might	  be	  
mixed	  non-­‐competitive	  at	  low	  phosphate,	  but	  is	  clearly	  uncompetitive	  at	  high	  
phosphate	  concentrations.	  	  Classical	  non-­‐competitive	  and	  competitive	  models	  of	  
inhibition	  did	  not	  fit	  the	  current	  data	  well.	  	  At	  10	  mM	  phosphate,	  and	  low	  
concentrations	  of	  BPTES,	  the	  inhibition	  data	  fits	  a	  mixed	  non-­‐competitive	  model	  
with	  smaller	  changes	  in	  Km	  than	  Vmax.	  	  The	  double	  reciprocal	  plots	  do	  not	  intersect	  
the	  x-­‐axis	  at	  the	  same	  point	  as	  seen	  in	  a	  strict	  non-­‐competitive	  inhibition	  model.	  	  
The	  linear	  fit	  of	  the	  double	  reciprocal	  plots	  all	  have	  a	  slightly	  different	  slope	  
indicating	  that	  the	  intersection	  of	  the	  DMSO	  control,	  0.1	  µM	  and	  0.3	  µM	  BPTES	  
occurs	  below	  the	  x-­‐axis.	  	  These	  observations	  all	  agree	  with	  a	  mixed	  non-­‐competitive	  
model.	  	  On	  the	  other	  hand,	  with	  30	  mM	  phosphate,	  the	  model	  of	  inhibition	  fits	  an	  
uncompetitive	  model.	  	  The	  saturation	  data	  transformed	  into	  double	  reciprocal	  plots	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show	  that	  at	  each	  concentration	  of	  BPTES	  there	  is	  equivalent	  changes	  in	  both	  Vmax	  
and	  Km.	  In	  the	  double	  reciprocal	  plots,	  the	  lines	  intersect	  the	  x-­‐axis	  and	  y-­‐axis	  at	  
different	  points.	  Furthermore,	  the	  lines	  of	  the	  double	  reciprocal	  plots	  differ	  from	  
those	  at	  10	  mM	  phosphate	  because	  the	  slopes	  are	  nearly	  identical	  for	  the	  DMSO	  
control,	  0.1	  µM,	  0.3	  µM,	  and	  0.6	  µM	  BPTES.	  	  The	  parallel	  behavior	  of	  the	  double	  
reciprocal	  plots	  is	  typical	  of	  uncompetitive	  inhibition,	  where	  both	  the	  Km	  and	  Vmax	  
change,	  but	  the	  slope	  of	  the	  line	  remains	  unchanged.	  	  
To	  further	  investigate	  the	  model	  of	  inhibition,	  the	  Ki	  for	  BPTES	  was	  calculated	  
using	  both	  the	  apparent	  Km	  and	  the	  apparent	  Vmax	  from	  the	  glutamine	  saturation	  
data	  at	  10	  mM	  and	  30	  mM	  phosphate.	  	  By	  plotting	  the	  apparent	  Vmax	  and	  the	  
apparent	  Km	  against	  the	  concentration	  of	  BPTES,	  the	  Ki	  was	  determined.	  	  At	  10	  mM	  
phosphate,	  the	  Ki	  values	  were	  0.14	  µM	  ±	  0.01	  µM	  and	  0.21	  ±	  0.06	  µM	  calculated	  from	  
the	  apparent	  Vmax	  and	  apparent	  Km,	  respectively.	  	  The	  slight	  change	  between	  the	  Ki	  
terms	  suggests	  the	  inhibition	  is	  might	  be	  mixed	  non-­‐competitive.	  However,	  these	  
changes	  are	  subtle	  indicating	  that	  an	  uncompetitive	  inhibition	  mechanism	  is	  
preferred.	  	  A	  change	  in	  Ki	  will	  alter	  both	  the	  slope	  and	  intercept	  in	  a	  double	  
reciprocal	  plot,	  as	  observed	  with	  the	  reported	  data	  at	  10	  mM	  phosphate	  and	  0.1	  µM	  
BPTES.	  	  At	  30	  mM	  phosphate,	  the	  Ki	  	  values	  were	  0.24	  ±	  0.03	  µM	  and	  0.16	  ±	  0.02	  µM	  
determined	  from	  the	  apparent	  Vmax	  and	  apparent	  Km,	  respectively.	  	  The	  Ki	  terms	  are	  
similar	  and	  correlate	  well	  with	  an	  uncompetitive	  model.	  	  Both	  the	  Km	  and	  Vmax	  
should	  change	  in	  an	  uncompetitive	  inhibition	  model,	  but	  because	  the	  calculated	  Ki	  
values	  were	  similar,	  the	  slope	  remains	  constant	  while	  the	  double	  reciprocal	  plots	  
are	  shifted	  along	  the	  y-­‐axis	  by	  the	  Ki	  inhibition	  term.	  	  The	  inhibition	  constant	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appears	  to	  be	  constant	  for	  both	  the	  10	  mM	  and	  30	  mM	  phosphate	  conditions	  
suggesting	  the	  inhibition,	  by	  BPTES,	  occur	  in	  an	  uncompetitive	  manner.	  
Phosphate	  is	  a	  known	  positive	  allosteric	  regulator	  of	  mammalian	  GA.	  	  As	  the	  
concentration	  of	  phosphate	  is	  increased,	  the	  specific	  activity	  of	  hKGA124-­‐551	  
increased.	  	  Phosphate	  activation	  profiles	  where	  performed	  with	  a	  range	  of	  5	  mM	  to	  
150	  mM	  phosphate	  in	  the	  presence	  of	  DMSO	  and	  BPTES.	  	  The	  presence	  of	  0.5	  µM	  
BPTES	  lowered	  the	  specific	  activity	  of	  hKGA124-­‐551	  by	  25%,	  while	  in	  the	  presence	  of	  
10	  µM	  BPTES	  the	  specific	  activity	  was	  decreased	  by	  75%	  when	  compared	  to	  the	  
DMSO	  control.	  	  From	  these	  data	  the	  K0.5	  for	  phosphate	  saturation	  was	  calculated.	  	  
Increasing	  the	  concentration	  of	  BPTES	  in	  the	  presence	  of	  increasing	  phosphate	  
concentration	  significantly	  increased	  the	  K0.5	  for	  phosphate	  suggesting	  a	  competition	  
for	  binding	  between	  BPTES	  and	  phosphate.	  	  Furthermore	  as	  the	  concentration	  of	  
BPTES	  was	  increased	  the	  Hill	  coefficients	  increased.	  	  In	  the	  DMSO	  control,	  the	  Hill	  
coefficient	  was	  1.3	  ±	  0.1	  µM	  suggesting	  there	  was	  little	  cooperativity	  in	  the	  binding	  
of	  phosphate.	  	  However,	  in	  the	  presence	  of	  10	  µM	  BPTES	  the	  Hill	  coefficient	  was	  2.2	  
±	  0.2	  µM	  indicating	  that	  at	  higher	  BPTES	  concentrations	  the	  binding	  of	  phosphate	  is	  
cooperative.	  	  The	  graph	  in	  Figure	  14	  depicts	  this	  as	  the	  DMSO	  control	  has	  a	  
hyperbolic	  curve	  whereas	  with	  10	  µM	  BPTES,	  the	  curve	  is	  sigmoidal.	  
To	  determine	  the	  molecular	  weight	  and	  oligomerization	  of	  hKGA124-­‐551	  gel	  
filtration	  chromatography	  and	  dynamic	  light	  scattering	  experiments	  were	  
performed.	  	  It	  has	  been	  established	  that	  mammalian	  isoforms	  of	  GA	  oligomerize	  in	  a	  
phosphate-­‐	  dependent	  manner	  (27).	  	  Studies	  suggest	  that	  the	  inactive	  form	  of	  KGA	  
exists	  as	  a	  dimer	  and	  the	  active	  complex	  of	  KGA	  is	  a	  tetramer	  or	  higher	  oligomer	  (7).	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Sedimentation-­‐velocity	  experiments	  performed	  in	  the	  presence	  of	  low	  and	  high	  
phosphate	  showed	  that	  BPTES	  binds	  and	  stabilizes	  the	  tetramer	  form	  of	  an	  N-­‐
terminal	  truncation	  of	  rat	  KGA.	  	  The	  gel	  filtration	  data	  suggest	  the	  hKGA124-­‐551	  
behaves	  in	  a	  similar	  fashion	  to	  the	  rat	  isoform.	  	  The	  molecular	  weight	  of	  hKGA124-­‐551	  
is	  46-­‐kDa,	  as	  calculated	  from	  its	  amino	  acid	  composition.	  	  In	  the	  presence	  of	  100	  mM	  
phosphate,	  and	  without	  BPTES,	  the	  predominant	  peak	  elutes	  from	  the	  column	  in	  a	  
100-­‐kDa	  species	  indicative	  of	  a	  dimer.	  	  The	  addition	  of	  BPTES,	  in	  the	  presence	  of	  
100	  mM	  phosphate,	  decreases	  the	  retention	  time.	  	  The	  protein	  now	  elutes	  from	  the	  
column	  with	  a	  retention	  time	  equivalent	  to	  a	  200-­‐kDa	  species,	  suggesting	  a	  tetramer	  
or	  higher	  oligomer.	  	  	  	  
Multi-­‐angle	  light	  scattering	  experiments	  were	  performed	  in	  the	  absence	  and	  
presence	  of	  BPTES	  at	  0	  mM	  phosphate	  and	  150	  mM	  phosphate.	  	  The	  addition	  of	  
phosphate	  in	  the	  absence	  or	  presence	  of	  BPTES	  produced	  no	  results.	  	  There	  was	  a	  
weak	  change	  in	  absorbance	  at	  280	  nm	  and	  no	  change	  in	  absorbance	  at	  230	  nm.	  	  
Furthermore,	  there	  was	  not	  a	  strong,	  or	  any	  scattering	  signal	  with	  the	  addition	  of	  
phosphate.	  	  However,	  in	  the	  absence	  of	  phosphate	  there	  was	  a	  larger	  change	  in	  
absorbance	  at	  280	  nm	  in	  the	  absence	  and	  presence	  of	  BPTES.	  	  The	  scattering	  signal	  
in	  the	  absence	  of	  phosphate	  was	  poor.	  	  These	  data	  did	  produce	  preliminary	  
molecular	  weight	  results	  suggesting	  a	  dimeric,	  100-­‐kDa,	  form	  in	  the	  absence	  of	  
BPTES,	  and	  a	  tetramer,	  200-­‐kDa,	  species	  in	  the	  presence	  of	  BPTES.	  	  However,	  due	  to	  
the	  error	  in	  these	  measurements	  and	  the	  poor	  quality	  of	  data,	  these	  preliminary	  
results	  are	  unreliable.	  	  Because	  the	  hKGA124-­‐551	  construct	  was	  not	  stable	  in	  solution	  
at	  concentrations	  higher	  than	  1.0	  mg/mL,	  it	  made	  multi-­‐angle	  light	  scattering	  
	  
46	  
measurements	  nearly	  impossible	  and	  very	  difficult	  to	  reproduce.	  	  Additional	  
experiments	  where	  designed	  using	  less	  complex	  buffers	  consisting	  of	  10	  mM	  Tris,	  
pH	  8.0,	  and	  150	  mM	  KCl	  at	  230	  nm	  using	  fresh	  sample	  purified	  within	  48	  hours,	  but	  
resulted	  in	  worse	  data	  collection.	  	  These	  findings	  indicated	  that	  without	  higher	  
concentrations	  of	  sample,	  the	  collected	  data	  could	  not	  be	  reliable	  and	  different	  
experimental	  techniques	  need	  to	  be	  pursued.	  	  Analytical	  ultra-­‐centrifugation	  (AUC)	  
studies	  would	  be	  more	  conclusive	  than	  multi-­‐angle	  light	  scattering,	  and	  would	  allow	  
accurate,	  reliable	  molecular	  weights	  of	  hKGA124-­‐551	  homodimerization	  to	  be	  
determined	  in	  the	  presence	  of	  phosphate	  and	  BPTES.	  	  Additionally,	  performing	  an	  
intensive	  buffer	  optimization	  may	  yield	  conditions	  that	  allow	  higher	  concentration	  
to	  be	  obtained.	  	  It	  was	  found	  that	  300	  mM	  KCl	  and	  at	  least	  10%	  glycerol	  were	  
essential	  to	  increasing	  the	  solubility	  of	  hKGA124-­‐551	  stored	  at	  4°C.	  	  Lower	  salt	  
concentrations	  and	  the	  removal	  of	  glycerol	  from	  the	  purification	  or	  SEC-­‐MALS	  
buffers	  increased	  the	  rate	  of	  protein	  precipitation	  drastically.	  	  
The	  combined	  kinetic	  profiles	  generate	  a	  possible,	  yet	  complex	  model	  for	  the	  
activation	  and	  inhibition	  of	  hKGA124-­‐551.	  	  Figure	  17	  describes	  the	  possible	  
mechanisms	  in	  which	  hKGA124-­‐551	  bind	  phosphate,	  substrate	  and	  inhibitor.	  	  In	  the	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Figure	  17	  Proposed	  mechanisms	  of	  hKGA124-­551	  in	  presence	  of	  phosphate	  
and	  BPTES	  
	  
The	  top	  (black)	  solid	  square	  is	  hKGA124-­‐551	  (E)	  in	  the	  absence	  of	  BPTES	  (I).	  	  E2	  and	  
E4	  describe	  the	  dimer	  and,	  or	  tetramer	  state	  the	  enzyme	  resides	  in.	  Moving	  from	  
the	  bottom	  to	  the	  top	  of	  the	  squares	  is	  the	  addition	  of	  phosphate	  (Pi)	  and	  moving	  
from	  the	  left	  of	  the	  squares	  to	  the	  right	  is	  the	  addition	  of	  glutamine,	  or	  the	  
substrate	  (S).	  	  The	  bottom	  (dashed)	  square	  is	  enzyme	  in	  the	  presence	  of	  inhibitor.	  	  
The	  solid	  (red)	  lines	  connecting	  the	  two	  squares	  is	  the	  addition	  of	  the	  inhibitor	  
BPTES.	  	  The	  arrows	  within	  each	  of	  the	  squares	  suggest	  the	  possible	  kinetic	  on	  
and	  off	  rates	  of	  each	  species.	  	  The	  small	  dashed	  arrow	  to	  the	  right	  of	  the	  cube	  is	  
the	  small	  probability	  product	  is	  formed	  in	  the	  absence	  of	  phosphate	  and	  the	  large	  




absence	  of	  inhibitor	  the	  enzyme	  can	  bind	  phosphate	  or	  substrate	  resulting	  in	  either	  
an	  enzyme	  substrate	  complex	  or	  an	  enzyme	  phosphate	  complex.	  	  The	  data	  indicate	  
higher	  concentrations	  of	  phosphate	  produce	  larger	  enzymatic	  activities,	  suggesting	  
the	  enzyme	  bound	  to	  phosphate	  is	  in	  an	  activated	  conformation	  and	  subsequently	  
binds	  substrate	  in	  a	  preferred	  manner	  compared	  to	  the	  absence	  of	  phosphate.	  	  The	  
enzyme-­‐phosphate-­‐substrate	  complex	  then	  performs	  catalysis	  resulting	  in	  the	  
production	  of	  glutamine.	  	  The	  addition	  of	  inhibitor	  to	  this	  mechanism	  generates	  four	  
additional	  binding	  possibilities;	  the	  enzyme-­‐inhibitor	  complex,	  the	  enzyme-­‐
substrate-­‐inhibitor	  complex,	  the	  enzyme-­‐phosphate-­‐inhibitor	  complex,	  and	  the	  
enzyme-­‐phosphate-­‐substrate-­‐inhibitor	  complex.	  	  	  
The	  data	  obtained	  from	  this	  study	  can	  rule	  out	  the	  enzyme-­‐inhibitor	  complex	  
because	  the	  inhibition	  data	  suggest	  the	  mechanism	  of	  inhibition	  is	  uncompetitive.	  	  
The	  binding	  of	  inhibitors	  with	  free	  enzyme	  is	  indicative	  of	  a	  competitive	  inhibition	  
mechanism,	  suggesting	  that	  the	  inhibitor	  competes	  with	  the	  substrate	  to	  bind	  the	  
enzymatic	  active	  site.	  	  A	  noncompetitive	  inhibitor	  can	  bind	  either	  free	  enzyme	  or	  
enzyme-­‐substrate	  complex	  allosterically	  resulting	  in	  a	  decreased	  Vmax	  but	  an	  
unchanged	  Km.	  The	  obtained	  data	  rule	  out	  this	  mechanism	  because	  the	  binding	  of	  
BPTES	  alters	  both	  the	  Vmax	  and	  Km	  suggesting	  that	  it	  does	  not	  bind	  both	  free	  enzyme	  
and	  enzyme-­‐substrate	  complex.	  	  However,	  an	  uncompetitive	  inhibitor	  preferentially	  
binds	  enzyme-­‐substrate	  complex	  altering	  both	  Vmax	  and	  Km.	  These	  combined	  data	  
now	  indicate	  the	  BPTES	  may	  preferentially	  bind	  to	  activated,	  phosphate-­‐bound,	  
hKGA124-­‐551	  in	  complex	  with	  glutamine.	  	  The	  data	  further	  suggest,	  as	  seen	  in	  
previous	  studies,	  that	  BPTES	  either	  binds	  to	  or	  forms	  a	  stable	  tetramer	  of	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mammalian	  GA.	  	  Because	  the	  data	  strongly	  indicate	  an	  uncompetitive	  inhibition	  
model,	  it	  can	  be	  proposed	  that	  BPTES	  only	  binds	  to	  enzyme-­‐substrate	  complex.	  	  If	  
this	  is	  valid,	  an	  enzyme-­‐substrate	  complex	  is	  preferentially	  observed	  when	  hKGA124-­‐
551	  exits	  in	  its	  tetramer	  form	  in	  the	  presence	  of	  phosphate.	  	  On	  the	  other	  hand,	  the	  
data	  can	  also	  suggest	  that	  BTPES	  alone	  is	  able	  to	  form,	  or	  induce,	  stable	  inactive	  
tetramer	  complexes	  of	  hKGA124-­‐551	  as	  seen	  in	  the	  gel	  filtration	  data	  (Figure	  11).	  	  In	  
the	  absence	  of	  phosphate	  mammalian	  GA,	  and	  hKGA124-­‐551	  exists	  as	  a	  dimer,	  
suggesting	  that	  BPTES	  may	  induce	  the	  formation	  of	  stable	  inactive	  tetramers	  bound	  
to	  substrate.	  	  This	  may	  explain	  the	  slight	  cooperativity	  seen	  for	  phosphate	  at	  higher	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10	  mM	  phosphate	  glutamine	  saturation	  profile	  
All	  Data	  Fit	   Apparent	  Km	   Apparent	  Vmax	   R	  Value	  
DMSO	   1.2±0.11	   8.8±0.17	   0.96	  
0.1	  µM	  BPTES	   0.9±0.10	   4.9±0.10	   0.94	  
0.3	  µM	  BPTES	   0.6±0.09	   2.7±0.07	   0.84	  
Mean	  Unweighted	   Apparent	  Km	   Apparent	  Vmax	   R	  Value	  
DMSO	   1.2±0.20	   8.8±0.30	   0.98	  
0.1	  µM	  BPTES	   0.9±0.16	   4.9±0.16	   0.97	  
0.3	  µM	  BPTES	   0.6±0.16	   2.7±0.13	   0.91	  
Mean	  Weighted	   Apparent	  Km	   Apparent	  Vmax	   R	  Value	  
DMSO	   0.8±0.03	   8.2±0.10	   0.98	  
0.1	  µM	  BPTES	   1.1±0.06	   4.9±0.07	   0.98	  
0.3	  µM	  BPTES	   0.5±0.05	   2.6±0.05	   0.92	  





30	  mM	  phosphate	  glutamine	  saturation	  profile	  
All	  Data	  Fit	   Apparent	  Km	   Apparent	  Vmax	   R	  Value	  
DMSO	   1.5±0.10	   23±0.32	   0.98	  
0.1	  µM	  BPTES	   0.9±0.06	   15±0.17	   0.98	  
0.3	  µM	  BPTES	   0.5±0.07	   9.6±0.20	   0.9	  
0.6	  µM	  BPTES	   0.4±0.05	   6.9±0.12	   0.89	  
1.0	  µM	  BPTES	   0.2±0.05	   5.3±0.12	   0.68	  
Mean	  Unweighted	   Apparent	  Km	   Apparent	  Vmax	   R	  Value	  
DMSO	   1.5±0.13	   23±0.43	   0.99	  
0.1	  µM	  BPTES	   0.9±0.08	   15±0.23	   0.99	  
0.3	  µM	  BPTES	   0.5±0.04	   9.6±0.13	   0.99	  
0.6	  µM	  BPTES	   0.4±0.06	   6.9±0.15	   0.97	  
1.0	  µM	  BPTES	   0.2±0.04	   5.3±0.10	   0.95	  
Mean	  Weighted	   Apparent	  Km	   Apparent	  Vmax	   R	  Value	  
DMSO	   1.6±0.04	   24±0.32	   1	  
0.1	  µM	  BPTES	   0.9±0.02	   15±0.16	   0.99	  
0.3	  µM	  BPTES	   0.6±0.04	   9.8±0.19	   0.99	  
0.6	  µM	  BPTES	   0.5±0.02	   7.1±0.12	   0.99	  
1.0	  µM	  BPTES	   0.3±0.03	   5.4±0.13	   0.98	  
	  
The	  specific	  activities,	  produced	  from	  the	  glutamine	  saturation	  profiles	  
at	  10	  mM	  and	  30	  mM	  phosphate,	  were	  curve	  fit	  to	  the	  Michaelis-­‐
Menten	  equation	  using	  KalidaGraph	  (Synergy)	  software.	  	  For	  each	  
concentration	  of	  phosphate	  the	  data	  was	  fit	  three	  different	  ways.	  	  The	  
all	  data	  fit	  was	  the	  saturation	  data	  fit	  for	  each	  of	  the	  five	  replicate	  data	  
points.	  	  The	  mean	  un-­‐weighted	  fit	  was	  the	  curve	  fit	  to	  the	  mean	  
saturation	  data	  without	  the	  standard	  error	  measurements	  included	  
into	  the	  curve	  fit.	  	  The	  mean	  weighted	  fit	  was	  the	  mean	  saturation	  data	  
with	  the	  standard	  error	  measurements	  included	  into	  the	  curve	  fit.	  	  The	  
apparent	  Km,	  the	  apparent	  Vmax,	  and	  the	  R-­‐values	  are	  the	  calculated	  
parameters	  produced	  by	  the	  non-­‐linear	  least	  squares	  fit	  performed	  by	  
KalidaGraph	  for	  each	  curve	  fit.	  
